it is fine idea to memorize those 310-232 modern dumps.

310-232 test questions | 310-232 free exam papers | 310-232 pass exam | 310-232 english practice test | 310-232 practice exam -

310-232 - Java EE6 Web services Developer(R) Certified Professional Eaxm - Dump Information

Vendor : SUN
Exam Code : 310-232
Exam Name : Java EE6 Web services Developer(R) Certified Professional Eaxm
Questions and Answers : 120 Q & A
Updated On : February 23, 2018
PDF Download Mirror : 310-232 Dump
Get Full Version : Pass4sure 310-232 Full Version

Pass4sure 310-232 Java EE6 Web services Developer(R) Certified Professional Eaxm exam braindumps with real questions and practice software.

We have our experts working continuously for the collection of real exam questions of 310-232. All the pass4sure questions and answers of 310-232 collected by our team are reviewed and updated by our 310-232 certified team. We remain connected to the candidates appeared in the 310-232 test to get their reviews about the 310-232 test, we collect 310-232 exam tips and tricks, their experience about the techniques used in the real 310-232 exam, the mistakes they done in the real test and then improve our material accordingly. Once you go through our pass4sure questions and answers, you will feel confident about all the topics of test and feel that your knowledge has been greatly improved. These pass4sure questions and answers are not just practice questions, these are real exam questions and answers that are enough to pass the 310-232 exam at first attempt.

SUN certifications are highly required across IT organizations. HR managers prefer candidates who not only have an understanding of the topic, but having completed certification exams in the subject. All the SUN certifications provided on Pass4sure are accepted worldwide.

Are you looking for pass4sure real exams questions and answers for the Java EE6 Web services Developer(R) Certified Professional Eaxm exam? We are here to provide you one most updated and quality sources that is They have compiled a database of questions from actual exams in order to let you prepare and pass 310-232 exam on the first attempt. All training materials on the site are up to date and verified by industry experts.

Why is the Ultimate choice for certification preparation?

1. A quality product that Help You Prepare for Your Exam: is the ultimate preparation source for passing the SUN 310-232 exam. We have carefully complied and assembled real exam questions and answers, which are updated with the same frequency as real exam is updated, and reviewed by industry experts. Our SUN certified experts from multiple organizations are talented and qualified / certified individuals who have reviewed each question and answer and explanation section in order to help you understand the concept and pass the SUN exam. The best way to prepare 310-232 exam is not reading a text book, but taking practice real questions and understanding the correct answers. Practice questions help prepare you for not only the concepts, but also the method in which questions and answer options are presented during the real exam.

2. User Friendly Mobile Device Access:

killexams provide extremely user friendly access to products. The focus of the website is to provide accurate, updated, and to the point material to help you study and pass the Java EE6 Web services Developer(R) Certified Professional Eaxm. You can quickly get the real questions and answer database. The site is mobile friendly to allow study anywhere, as long as you have internet connection. You can just load the PDF in mobile and study anywhere.

3. Access the Most Recent Java EE6 Web services Developer(R) Certified Professional Eaxm Real Questions & Answers:

Our Exam databases are regularly updated throughout the year to include the latest real questions and answers from the SUN 310-232 exam. Having Accurate, authentic and current real exam questions, you will pass your exam on the first try!

4. Our Materials is Verified by Industry Experts:

We are doing struggle to providing you with accurate Java EE6 Web services Developer(R) Certified Professional Eaxm exam questions & answers, along with explanations. We make the value of your time and money, that is why every question and answer on Pass4sure has been verified by SUN certified experts. They are highly qualified and certified individuals, who have many years of professional experience related to the SUN exams.

5. We Provide all Exam Questions and Include Detailed Answers with Explanations: Huge Discount Coupons and Promo Codes are as under;
WC2017 : 60% Discount Coupon for all exams on website
PROF17 : 10% Discount Coupon for Orders greater than $69
DEAL17 : 15% Discount Coupon for Orders greater than $99
DECSPECIAL : 10% Special Discount Coupon for All Orders

Unlike many other exam prep websites, provides not only updated actual SUN 310-232 exam questions, but also detailed answers, explanations and diagrams. This is important to help the candidate not only understand the correct answer, but also details about the options that were incorrect.

Discount Coupon, Promo Codes, 310-232 vce, Free 310-232 vce, Download Free 310-232 dumps, Free 310-232 braindumps, pass4sure 310-232, 310-232 practice test, 310-232 practice exam, 310-232, 310-232 real questions, 310-232 actual test, 310-232 PDF download, Pass4sure 310-232 Download, 310-232 help, 310-232 examcollection, Passleader 310-232, exam-labs 310-232, Justcertify 310-232, certqueen 310-232, 310-232 testking

View Full Exam »

Little observe for 310-232 examination, first rate success.

It become very encourging revel in with crew. They informed me to attempt their 310-232 examination questions once and neglect failing the 310-232 exam. First I hesitated to apply the material because I afraid of failing the 310-232 examination. however after I told by using my friends that they used the exam simulator for thier 310-232 certification examination, i bought the coaching p.c.. It became very cheap. That was the primary time that I satisfied to apply guidance fabric after I got 100% marks in my 310-232 examination. I in reality respect you team.

located an accurate source for actual 310-232 Questions.

Going through Q&A has become a habit when exam 310-232 comes. And with exams coming up in just about 6 days Q&A was getting more important. But with topics I need some reference guide to go once in a while so that I would get better help. Thanks to their Q&A that made it all easy to get the topics inside your head easily which would otherwise would be impossible. And it is all because of products that I managed to score 980 in my exam. Thats the highest score in my class.

It is right place to find 310-232 dumps paper.

After 2 times taking my exam and failed, I heard about Guarantee. Then I bought 310-232 Questions Answers. Online Testing Engine helped me to training to solve question in time. I simulated this test for many times and this help me to keep focus on questions at examination day.Now I am an IT Certified! Thanks!

Unbelieveable! but proper source of 310-232 real take a look at questions.

To grow to be a 310-232 licensed, i used to be in push to pass the 310-232 exam. I attempted and failed ultimate 2 tries. Accidently, I were given the fabric through my cousin. i was very impressed with the Q&a material. I secured 89%. i am so glad that I scored above the margin mark with out problem. The fabric is properly formatted as well as enriched with vital concepts. I think it's miles the fantastic desire for the exam.

i found the entirety had to bypass 310-232 exam here.

I passed. proper, the examination become tough, so I simply got past it attributable to Q&A and examSimulator. i am upbeat to document that I passed the 310-232 examination and feature as of past due obtained my statement. The framework inquiries were the component i was most harassed over, so I invested hours honing on exam simulator. It beyond any doubt helped, as consolidated with distinct segments.

Is there 310-232 examination new sayllabus to be had?

Many thanks for your 310-232 dumps. I recognized most of the questions and you had all the simulations that I was asked. I got 97 percent score. After trying several books, I was quite disappointed not getting the right materials. I was looking for a guideline for exam 310-232 with simple language and well-organized content. Q&A fulfilled my need, as it explained the complex topics in the simplest way. In the real exam I got 97%, which was beyond my expectation. Thank you killexams, for your great guide-line!

What do you mean by 310-232 exam?

I practically lost trust in me in the wake of falling flat the 310-232 exam.I scored 87% and cleared this exam. Much obliged for recovering my certainty. Subjects in 310-232 were truly troublesome for me to get it. I practically surrendered the plan to take this exam once more. Anyway because of my companion who prescribed me to use Questions & Answers. Inside a compass of simple four weeks I was completely ready for this exam.

What is needed to examine for 310-232 examination?

i've these days passed the 310-232 exam with this bundle. that is a great answer if you need a quick yet dependable coaching for 310-232 examination. this is a expert level, so expect that you nevertheless need to spend time gambling with Q&A - practical enjoy is fundamental. yet, as far and exam simulations cross, Killexams is the winner. Their checking out engine clearly simulates the examination, such as the unique question types. It does make things less complicated, and in my case, I trust it contributed to me getting a one hundred% score! I could not consider my eyes! I knew I did nicely, but this became a marvel!!

it is unbelieveable, but 310-232 braindumps are availabe right here.

a few properly men cant bring an alteration to the worlds way however they can most effective inform you whether you have got been the simplest man who knew how to do that and i want to be acknowledged on this world and make my personal mark and i've been so lame my complete way but I realize now that I wanted to get a bypass in my 310-232 and this could make me well-known perhaps and yes i'm quick of glory however passing my A+ checks with changed into my morning and night glory.

it is splendid to have 310-232 modern-day Braindumps.

I was about to give up exam 310-232 because I wasnt confident in whether I would pass or not. With just a week remaining I decided to switch to Q&A for my exam preparation. Never thought that the topics that I had always run away from would be so much fun to study; its easy and short way of getting to the points made my preparation lot easier. All thanks to Q&A, I never thought I would pass my exam but I did pass with flying colors.

See more SUN dumps

310-065 | 311-019 | 310-066 | 310-303 | 310-015 | 310-811 | 310-019 | 310-620 | 310-880 | 212-055 | 310-110 | 310-055 | 310-053 | 310-540 | 310-011 | 310-100 | 310-615 | 310-152 | 310-056 | 310-875 | 310-102 | 310-150 | 310-876 | 310-200 | 310-083 | 310-610 | 310-091 | 310-502 | 310-036 | 310-014 | 310-330 | 310-052 | 310-220 | 310-302 | 310-101 | 310-301 | 310-203 | 310-345 | 310-043 | 310-400 | 310-084 | 310-560 | 212-065 | 310-814 | 310-878 | 311-232 | 310-812 | 310-105 | 310-013 | 310-813 |

Latest Exams added on morganstudioonline

1Z0-453 | 210-250 | 300-210 | 500-205 | 500-210 | 70-765 | 9A0-409 | C2010-555 | C2090-136 | C9010-260 | C9010-262 | C9020-560 | C9020-568 | C9050-042 | C9050-548 | C9050-549 | C9510-819 | C9520-911 | C9520-923 | C9520-928 | C9520-929 | C9550-512 | CPIM-BSP | C_TADM70_73 | C_TB1200_92 | C_TBW60_74 | C_TPLM22_64 | C_TPLM50_95 | DNDNS-200 | DSDPS-200 | E20-562 | E20-624 | E_HANABW151 | E_HANAINS151 | JN0-1330 | JN0-346 | JN0-661 | MA0-104 | MB2-711 | NSE6 | OMG-OCRES-A300 | P5050-031 |

See more dumps on morganstudioonline

310-540 | EE0-502 | JN0-530 | NS0-504 | MK0-201 | HP0-J48 | HP3-C24 | 70-463 | LOT-958 | 1Z0-100 | C2010-568 | M8060-729 | C_SAPXIMP_20 | A30-327 | HP0-S31 | LOT-923 | 310-540 | 050-892 | C_TCRM20_71 | 920-245 | 644-337 | HP5-E01D | PEGACMBB | C2010-569 | 1V0-601 | 00M-530 | 000-136 | HP2-E51 | 1D0-520 | 000-155 | PW0-104 | 7304 | 700-302 | HP2-H08 | TB0-104 | 1Z0-540 | JN0-130 | 9A0-056 | 7303-1 | 000-869 | 1Z0-416 | 000-975 | 300-165 | F50-531 | HP2-B88 | M2040-669 | 00M-652 | C2090-719 | HP2-H40 | HP2-H08 |

310-232 Questions and Answers



Which two code fragments are valid for adding an attachment in SAAJ? (Choose two.)

  1. AttachmentPart attachment = request.createAttachementPart(); String stringContent = Update total;

    attachment.setContent(stringContent,text/plain); attachment.setContentID(update_total); request.addAttachmentPart(attachment);

  2. Attachment attachment = request.createAttachement();

    String stringContent = Update total; attachment.setContent(stringContent,text/plain); attachment.setContentID(update_total); request.addAttachment(attachment);

  3. URL url = new URL(; DataHandler datahandler = new DataHandler(url); AttachmentPart attachment = request.createAttachmentPart(dataHandler); attachment.setContentID (attached_image); request.addAttachmentPart(attachment);

  4. URL url = new URL(; DataHandler datahandler = new DataHandler(url); Attachment attachment = request.createAttachment(dataHandler); attachment.setContentID (attached_image); request.addAttachment(attachment);

  5. Attachment attachment = request.newAttachement();

String stringContent = Update total; attachment.setContent(stringContent,text/plain); attachment.setContentID(update_total); request.setAttachment(attachment);

Answer: A,C


A developer must create a program to parse a medium-sized XML file looking for an instance of a specific element. Once the developer has found the element, the value must be updated and saved to disk. Which two XML parsing APIs should be used in this situation? (Choose two.)

  1. DOM

  2. StAX

  3. JAXM

  4. SAAJ

Answer: A,B


Which two statements are true about creating a Web service with JAX-WS? (Choose two.)

  1. Stateless Web services must be created with HTTP servlet endpoints.

  2. Creating the portable artifacts by hand is slow, but makes a service easier to maintain.

  3. All Java-based endpoints share a common packaging model.

  4. EJBs can serve as endpoints if hosted in a container with runtime and service support.

  5. JAX-WS supports creating services from source and compiled code without a WSDL.

Answer: D,E


What are two features of a WSDL 1.1 document? (Choose two.)

  1. Service defines a collection of related endpoints.

  2. Service describes the message's payload using XML.

  3. Service assigns an Internet address to a specific binding.

  4. Porttype declares complex data types and elements used elsewhere.

  5. Porttype elements are used to group a set of abstract operations.

  6. Porttype defines a concrete protocol and data format specification.

Answer: A,E


Given that a developer implemented a web service using Stateless Session EJB:

If a web service client invokes increment web service method twice consecutively, what must be the returned value after the second invocation ? (Choose one)

  1. 0

  2. 1

  3. 2

  4. 3

  5. Undefined

Answer: E


A student developer has created a new library of math functions to share with friends in a linear algebra class. The developer is having difficulty getting people to come over to the dorm to see the new code library, so he decides to deploy it as a Web service so that everyone can enjoy the features via the Internet. One of the functions has this WSDL definition:

<portType name="MyMathLib"><operation name="incCtr"><input message="tns:incCtr"/></operation></portType>

Which two statements are true about this Web service? (Choose two.)

  1. This is an asynchronous receive.

  2. This indicates a one-way message exchange pattern

  3. The client must use SOAPFaultException to display any errors.

  4. It must send a SOAP fault back to the sender.

  5. It must NOT send a SOAP fault back to the sender.

Answer: B,E


An organization has business logic implemented in EJB components. Current clients use container-managed, role-based security to access the business logic using RMI. Management has determined that the business logic must be made available to non-RMI clients using a Web service. Which container-managed Web service security mechanism would the development team? use to allow Web service clients to use the current security model? (Choose one)

  1. XKMS

  2. XACML

  3. XML Digital Signature

  4. HTTP Basic Authentication

  5. annotations mapped to the JAX-WS runtime

Answer: D

SUN 310-232 Exam (Java EE6 Web services Developer(R) Certified Professional Eaxm) Detailed Information

Article by ArticleForge

Sunshine Magazine February 2012

Situated - Camposol, Mazarron Well furnished villa, pool with large private patio, English TV Gated driveway, Central heating, Sun room, AC ... rent from 25 March 2011 from 125€ per week 646 310 232 For rent Apartment for rent in Puerto de Mazarrón ...Article by ArticleForge

Wilkens Takes Over Raptors

Actors Shannon Elizabeth and Clifton Collins Jr. at the premiere of "Runaway Jury" in Los Angeles on Oct. 9, 2003. In 2003, Collins guest-starred in three episodes of the ABC drama "Alias."

ImagesKevin Winter

Lenny Wilkens, the winningest coach in NBA history, was hired by the Toronto Raptors on Wednesday to try to stabilize a team in disarray.

The Toronto Sun reported the Hall of Famer had signed a $20 million contract to coach the team for four years.

"I'm excited about it and can't wait to get started," Wilkens said at a news conference.

The 62-year-old coach replaces Butch Carter, who was fired June 13 despite leading the team to the playoffs. But Carter questioned his team's leadership and was embroiled in one dispute after another this season. He also wanted the title of general manager.

"I like the team, I like the city," Wilkens said. "I've watched the Raptors, I've coached against them. I thought last year they made a tremendous stride getting to the playoffs and I think their future is all upward."

Wilkens quit as coach of the Atlanta Hawks after the season. The Sun said he is owed $10.4 million by the Hawks over the next two seasons, with his Toronto salary to be deducted from that amount.

The Hawks finished 28-54 this season, next to last in the Eastern Conference. It was the worst season of his 27-year coaching career and the worst for the Hawks since the franchise moved to Atlanta in 1968.

"I was aware that there were some issues down there in Atlanta and there was some grumblings things might change there," Toronto general manager Glen Grunwald said.

"But, really, in my wildest dreams, I wouldn't have thought that we could have of obtained a coach of Lenny's character and quality. For our franchise this is the best thing possible."

Wilkens, who said the Raptors "exude class from the top down," becomes the fourth head coach in the team's five years. He brings an impeccable resume to a job filled previously by Brendan Malone, Darrell Walker and Carter, all first-time head coaches.

Center Kevin Willis, the only Raptors player coached previously by Wilkens, said hiring him was a smart move.

"The older guys will respect Lenny instantly, and to me that's the most important thing," Willis, who played under Wilkens on the Atlanta Hawks, said.

Wilkens has coached in Seattle, Portland, Cleveland and Atlanta. He has a record of 1,179-981, and in seven years with Atlanta had a mark of ">310-232. He has guided a club to 50 or more regular-season victories nine times and in 1979 led the SuperSonics to their lone NBA title.

Wilkens has been in Toronto since Monday. He met with Grunwald, team president Richard Peddie and minority owner Lary Tanenbaum on Monday night. On Tuesday, Wilkens was introduced to the Maple Leaf Sports and Entertainment Ltd. board of directors.

Wilkens carries a reputation as a player's coach. His soft-spoken approach would appear to be a good fit for the Raptors, whose veterans became disenchanted with Carter.

At the end of the year, Carter threatened to sue Marcus Camby of the New York Knicks for defamation before changing his mind. At the same time, he said the his players' contract issues accounted for their playoff loss to the Knicks.

Wilkens faces a handful of tough personnel decisions if Grunwald doesn't shake up the roster between now and the opening of training camp.

The team boasts Vince Carter but needs a center and a point guard and faces the likely departure of Tracy McGrady.

Wilkens and UCLA's John Wooden are the only individuals in the Basketball Hall of Fame as both a coach and player. In 1997-98, Wilkens was named among the NBA's top 10 coaches and 50 greatest players, the only person to make both lists.

Wilkens coached the United States to an Olympic gold medal in 1996 after serving as an assistant with the original Dream Team that won the Olympic title in 1992.

Wilkens was a first-round draft pick out of Providence and spent 15 years as a player with St. Louis, Seattle and Cleveland. He ranks among the career leaders in assists, games played and free throws made.

2000 The . . This material may not be rewritten, or redistributed

2000 Interactive . . This material may not be rewritten, or redistributed. The contributed to this report.

Article by ArticleForge

Does the Trenberth et al “Earth’s Energy Budget Diagram” Contain a Paradox?

Guest post by Bob Fernley-Jones by Bob Fernley-Jones AKA Bob_FJ

CAUTION: This is written in Anglo-Oz English.

Here is the diagram as extracted from their 2009 paper, it being an update of that in the IPCC report of 2007 (& also 2001):

The unusual aspect of this diagram is that instead of directly showing radiative Heat Transfer  from the surface, it gives their depiction of the greenhouse effect in terms of radiation flux or Electro-Magnetic Radiation, (AKA; EMR and a number of other descriptions of conflict between applied scientists and physicists).  EMR is a form of energy that is sometimes confused with HEAT.  It will be explained later, that the 396 Wm^2 surface radiation depicted above has very different behaviour to HEAT.  Furthermore, temperature change in matter can only take place when there is a HEAT transfer, regardless of how much EMR is whizzing around in the atmosphere.

A more popular schematic from various divisions around NASA and Wikipedia etc, is next, and it avoids the issue above:

Figure 2                                                     NASA

Returning to the Trenberth et al paper, (link is in line 1 above), they give that the 396 Wm2 of EMR emitted from the surface in Fig.1 is calculated primarily by using the Stefan–Boltzmann law, and global year average conditions.  Putting aside a few lesser but rather significant issues therein, it is useful to know that:

1) The Stefan-Boltzmann law (S-B) describes the total emission from a flat surface that is equally radiated in all directions, (is isotropichemispherical).  Stefan found this via experimental measurement, and later his student Boltzmann derived it mathematically.

2) The validity of equally distributed hemispherical EMR is demonstrated quite well by observing the Sun. (with eye protection).  It appears to be a flat disc of uniform brightness, but of course it is a sphere, and at its outer edge, the radiation towards Earth is tangential from its apparent surface, not vertical.  It is not a perfect demonstration because of a phenomenon called limb darkening, due to the Sun not having a definable surface, but actually plasma with opacity effects.  However, it is generally not apparent to the eye and the normally observed (shielded) eyeball observation is arguably adequate for purpose here.

3) Whilst reportedly the original Stefan lab test was for a small flat body radiating into a hemisphere, its conclusions can be extended to larger areas by simple addition of many small flat bodies of collectively flat configuration, because of the ability of EMR waves to pass through each other.   This can be demonstrated by car driving at night, when approaching headlights do not change in brightness as a consequence of your own headlights opposing them.  (not to be confused with any dazzling effects and fringe illumination)

4) My sketch below demonstrates how radiation is at its greatest concentration in the lateral directions.  It applies to both the initial S-B hemispherical surface radiation and to subsequent spherical radiation from the atmosphere itself.

 5) Expanding on the text in Figure 3:  Air temperature decreases with altitude, (with lapse rate), but if we take any thin layer of air over a small region, and time interval, and with little turbulence, the temperature in the layer can be treated as constant.  Yet, the most concentrated radiation within the layer is horizontal in all directions, but with a net heat transfer of zero.  Where the radiation is not perfectly horizontal, adjacent layers will provide interception of it.

A more concise way of looking at it is with vectors, which put simply is a mathematical method for analysing parameters that possess directional information.  Figure 4, takes a random ray of EMR (C) at a modestly shallow angle, and analyses its vertical and horizontal vector components.  The length of each vector is proportional to the power of the ray, in that direction, such that A + B = C.  Of course this figure is only in 2D, and there are countless multi-directional rays in 3D, with the majority approaching the horizontal, through 360 planar degrees, where the vertical components also approach zero.

6) Trenberth’s figure 1 gives that 65% of the HEAT loss from the surface is via thermals and evapo-transpiration.  What is not elaborated is that as a consequence of this upward HEAT transfer, additional infrared radiation takes place in the air column by virtue of it being warmed.  This initially starts as spherical emission and absorption, but as the air progressively thins upwards, absorption slows, and that radiation ultimately escapes directly to space.  Thus, the infrared radiation observable from space has complex sources from various altitudes, but has no labels to say where it came from, making some of the attributions “difficult”.

DISCUSSION;  So what to make of this?

The initial isotropic S-B surface emission, (Trenberth’s global 396 Wm2), would largely be absorbed by the greenhouse gases instantaneously near the surface. (ignoring some escaping directly to space through the so-called “atmospheric window”).  However, a large proportion of the initial S-B 396 surface emission would be continuously lateral, at the Trenberth imposed constant conditions, without any heat transfer, and its horizontal vectors CANNOT be part of the alleged 396 vertical flux, because they are outside of the vertical field of view.

After the initial atmospheric absorptions, the S-B law, which applied initially to the surface, no longer applies to the air above. (although some clouds are sometimes considered to be not far-off from a black body).  Most of the air’s initial absorptionemission is close to the surface, but the vertical distribution range is large, because of considerable variation in the photon free path lengths.  These vary with many factors, a big one being the regional and more powerful GHG water vapour level range which varies globally between around ~0 to ~4%.  (compared with CO2 at a somewhat constant ~0.04%).  The total complexities in attempting to modelcalculate what may be happening are huge and beyond the scope of this here, but the point is that every layer of air at ascending altitudes continuously possesses a great deal of lateral radiation that is partly driven by the S-B hemispherical 396, but cannot therefore be part of the vertical 396 claimed in Figure 1.


The vertical radiative flux portrayed by Trenberth et al of 396 Wm^2 ascending from the surface to a high cloud level is not supported by first principle considerations.   The S-B 396 Wm^2 is by definition isotropic as also is its ascending progeny, with always prevailing horizontal vector components that are not in the field of view of the vertical.  The remaining vertical components of EMR from that source are thus less than 396 Wm^2.

It is apparent that HEAT loss from the surface via convectiveevaporative processes must add to the real vertical EMR loss from the surface, and as observed from space.  It may be that there is a resultant of similar order to 396 Wm^2, but that is NOT the S-B radiative process described by Trenberth.



I Seek your advice

In figure 5 below, note that the NIMBUS 4 satellite data on the left must be for ALL sources of radiation as seen from space, in this case, at some point over the tropical Pacific.  The total emissions, amount to the integrated area under the curve, which unfortunately is not given.  However, for comparison purposes, a MODTRAN calculator, looking down from 100 Km gives some interesting information for the figure, which is further elaborated in the tables below.  Unfortunately the calculator does not give global data or average cloudsky conditions, so we have apples and pears to compare, not only with Nimbus, but also with Trenberth.  However, they all seem to be of somewhat similar order, and see the additional tabulations.

Compare MODTRAN & “Trenberth”, looking down from 2 altitudes, plus Surface Temperature Location Kelvin 10 metres 100 Km. (Centigrade) Tropical Atmosphere 300K 419 Wm^2 288 Wm^2 (27C) Mid-latitude Summer 294K 391 Wm^2 280 Wm^2 (21C) Mid-latitude Winter 272K 291 Wm^2 228 Wm^2 (-1C) Sub-Arctic Winter 257K 235 Wm^2 196 Wm^2 (-16C) Trenberth Global 288K ? 396  Wm^2 239 Wm^2 (15C ?) Compare MODTRAN & “Trenberth”, looking UP from 4 altitudes:  Wm^2 Location From 10 m From 2 Km From 4Km From 6Km Tropical Atmosphere 348 252 181 125 Mid-latitude Summer 310 232 168 118 Mid-latitude Winter 206 161 115 75 Sub-Arctic Winter 162 132 94 58 Trenberth Global 333     Shown as coming from  high cloud area  (= BS according to MODTRAN)

Article by ArticleForge

Using Exam Topics As Your Guide

Please remember to use the Exam Topics list as your guide when you study for Oracle certification exams. The Exam Topics are available for every single exam on the "exam details" page. I suggest that you use the Exam Topics to create a table and rate your ...Article by ArticleForge

ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis

  • 1

    David Wyles, Jennifer Lin. . 2017. Clinical Manifestations of Acute and Chronic Hepatitis. Infectious Diseases, 363-374.e4. CrossRef

  • 2

    Leah A. Burke, Kristen M. Marks. . 2017. Drugs to Treat Viral Hepatitis. Infectious Diseases, 1327-1332.e1. CrossRef

  • 3

    C. Nelson Hayes, Michio Imamura, Kazuaki Chayama. . 2017. Emerging Antivirals in the Future. Hepatitis C Virus Treatment, 63-75. CrossRef

  • 4

    Jennifer R. Reed, Ashly E. Jordan, David C. Perlman, Daniel J. Smith, Holly Hagan. . (2016) The HCV care continuum among people who use drugs: protocol for a systematic review and meta-analysis. Systematic Reviews 5:1. CrossRef

  • 5

    Daniel M. Forton. . (2016) How much of a problem is resistance in treating hepatitis C?. Current Opinion in Infectious Diseases 29:6, 625-631. CrossRef

  • 6

    Raoel Maan, Marjolein van Tilborg, Katja Deterding, Alnoor Ramji, Adriaan J. van der Meer, Florence Wong, Scott Fung, Morris Sherman, Michael P. Manns, Markus Cornberg, Bettina E. Hansen, Heiner Wedemeyer, Harry L.A. Janssen, Robert J. de Knegt, Jordan J. Feld. . (2016) Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology 14:12, 1821-1830.e6. CrossRef

  • 7

    Mohamed El Kassas, Tamer Elbaz, Enas Hafez, Gamal Esmat. . (2016) Safety of direct antiviral agents in the management of hepatitis C. Expert Opinion on Drug Safety 15:12, 1643-1652. CrossRef

  • 8

    Emma Gray, Suzanne Norris, Susanne Schmitz, Aisling O'Leary. . (2016) Do disparities between populations in randomized controlled trials and the real world lead to differences in outcomes?. Journal of Comparative Effectiveness Research. CrossRef

  • 9

    Sven Mensing, Doerthe Eckert, Shringi Sharma, Akshanth R. Polepally, Amit Khatri, Thomas J. Podsadecki, Walid M. Awni, Rajeev M. Menon, Sandeep Dutta. . (2016) Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. British Journal of Clinical Pharmacology. CrossRef

  • 10

    Lan S. Wang, Lionel S. D'Souza, Ira M. Jacobson. . (2016) Hepatitis C-A clinical review. Journal of Medical Virology 88:11, 1844-1855. CrossRef

  • 11

    José R. Blanco, Antonio Rivero-Juárez. . (2016) The risk of hepatocellular carcinoma after sustained virological response in patients treated with the new direct-acting antiviral drugs: should we be worry about it?. Expert Review of Anti-infective Therapy 14:11, 993-996. CrossRef

  • 12

    Vicente Gimeno-Ballester, Miguel Ángel Simón, Cristina Trigo, Javier Mar, Ramón San Miguel. . (2016) Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence. Expert Review of Gastroenterology & Hepatology 10:11, 1289-1303. CrossRef

  • 13

    A. A. Butt, Y. Ren, K. Marks, O. S. Shaikh, K. E. Sherman, . . (2016) Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES. Alimentary Pharmacology & Therapeutics. CrossRef

  • 14

    Narcyz Ghinea, Wendy Lipworth, Richard Day, Andrew Hill, Gregory J Dore, Mark Danta. . (2016) Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries. The Lancet. CrossRef

  • 15

    C. Hézode. . (2016) Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions. Journal of Viral Hepatitis. CrossRef

  • 16

    Lize Cuypers, Francesca Ceccherini-Silberstein, Kristel Van Laethem, Guangdi Li, Anne-Mieke Vandamme, Jürgen Kurt Rockstroh. . (2016) Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Reviews in Medical Virology 26:6, -434. CrossRef

  • 17

    Marcello Maida, Giuseppe Malizia, Andrea Affronti, Roberto Virdone, Carlo Maida, Vito Margherita, Gennaro D’amico. . (2016) Screening and surveillance for hepatocellular carcinoma: perspective of a new era?. Expert Review of Anticancer Therapy, 1-12. CrossRef

  • 18

    Noboru Hirashima, Hiroaki Iwase, Masaaki Shimada, Nobumitsu Ryuge, Junji Imamura, Hiroki Ikeda, Yasuhito Tanaka, Nobuyuki Matsumoto, Chiaki Okuse, Fumio Itoh, Yoshiyuki Yokomaku, Tsunamasa Watanabe. . (2016) Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir. Clinical Journal of Gastroenterology. CrossRef

  • 19

    John J. Faragon. . (2016) Drug Interactions Associated with HIV and HCV Medications. Current Treatment Options in Infectious Diseases. CrossRef

  • 20

    Zobair M. Younossi, Maria Stepanova, Mark Sulkowski, Graham R. Foster, Nancy Reau, Alessandra Mangia, Keyur Patel, Norbert Bräu, Stuart K. Roberts, Nezam Afdhal, Fatema Nader, Linda Henry, Sharon Hunt. . (2016) Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Clinical Infectious Diseases 63:8, 1042-1048. CrossRef

  • 21

    A. D. Marshall, S. Saeed, L. Barrett, C. L. Cooper, C. Treloar, J. Bruneau, J. J. Feld, L. Gallagher, M. B. Klein, M. Krajden, N. H. Shoukry, L. E. Taylor, J. Grebely, . . (2016) Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open 4:4, E605-E614. CrossRef

  • 22

    Scott J. Johnson, Hélène Parisé, Suchin Virabhak, Ivana Filipovic, Jennifer C. Samp, Derek Misurski. . (2016) Economic evaluation of ombitasvirparitaprevirritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. Journal of Medical Economics 19:10, 983-994. CrossRef

  • 23

    Nicola Coppola, Carmine Minichini, Mario Starace, Caterina Sagnelli, Evangelista Sagnelli. . (2016) Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. Journal of Medical Virology 88:10, 1659-1671. CrossRef

  • 24

    V. L. Ferreira, N. A. Assis Jarek, F. S. Tonin, H. H. L. Borba, A. Wiens, R. Pontarolo. . (2016) Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. Journal of Clinical Pharmacy and Therapeutics 41:5, 478-485. CrossRef

  • 25

    A. A. Butt, P. Yan, K. Marks, O. S. Shaikh, K. E. Sherman, . . (2016) Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES. Alimentary Pharmacology & Therapeutics 44:7, 728-737. CrossRef

  • 26

    Prajakta S. Badri, Apurvasena Parikh, Eoin P. Coakley, Bifeng Ding, Walid M. Awni, Sandeep Dutta, Rajeev M. Menon. . (2016) Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. Therapeutic Drug Monitoring 38:5, 640-645. CrossRef

  • 27

    Benjamin Maasoumy, Johannes Vermehren. . (2016) Diagnostics in hepatitis C: The end of response-guided therapy?. Journal of Hepatology 65:1, S67-S81. CrossRef

  • 28

    Jordan J. Feld, Graham R. Foster. . (2016) Second generation direct-acting antivirals – Do we expect major improvements?. Journal of Hepatology 65:1, S130-S142. CrossRef

  • 29

    María Reig, Zoe Mariño, Christie Perelló, Mercedes Iñarrairaegui, Andrea Ribeiro, Sabela Lens, Alba Díaz, Ramón Vilana, Anna Darnell, María Varela, Bruno Sangro, José Luis Calleja, Xavier Forns, Jordi Bruix. . (2016) Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. Journal of Hepatology 65:4, 719-726. CrossRef

  • 30

    Zobair M. Younossi, Haesuk Park, Douglas Dieterich, Sammy Saab, Aijaz Ahmed, Stuart C. Gordon. . (2016) Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States. Medicine 95:41, e5048. CrossRef

  • 31

    Salvatore Petta, Vito Di Marco, Savino Bruno, Marco Enea, Vincenza Calvaruso, Vincenzo Boccaccio, Sonia Rossi, Antonio Craxì, Calogero Cammà. . (2016) Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Liver International. CrossRef

  • 32

    Jia-Horng Kao, Shui-Yi Tung, Younjae Lee, Satawat Thongsawat, Tawesak Tanwandee, I.-Shyan Sheen, Jinzi J. Wu, Hui Li, Barbara J. Brennan, Julian Zhou, Sophie Le Pogam, Isabel Najera, James A. Thommes, George Hill. . (2016) Ritonavir-boosted danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic hepatitis C patients with or without cirrhosis. Journal of Gastroenterology and Hepatology 31:10, 1757-1765. CrossRef

  • 33

    J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman. . (2016) Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice. Clinical Microbiology and Infection 22:10, 846-852. CrossRef

  • 34

    Adriaan J. van der Meer, Jordan J. Feld, Harald Hofer, Piero L. Almasio, Vincenza Calvaruso, Conrado M. Fernández-Rodríguez, Soo Aleman, Nathalie Ganne-Carrié, Roberta D’Ambrosio, Stanislas Pol, Maria Trapero-Marugan, Raoel Maan, Ricardo Moreno-Otero, Vincent Mallet, Rolf Hultcrantz, Ola Weiland, Karoline Rutter, Vito Di Marco, Sonia Alonso, Savino Bruno, Massimo Colombo, Robert J. de Knegt, Bart J. Veldt, Bettina E. Hansen, Harry L.A. Janssen. . (2016) Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. Journal of Hepatology. CrossRef

  • 35

    Olivier Ethgen, Yuri Sanchez Gonzalez, Grégoire Jeanblanc, Aurore Duguet, Derek Misurski, Timothy Juday. . (2016) Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population. Journal of Medical Economics, 1-9. CrossRef

  • 36

    Perica Davitkov, Melissa K. Osborn, Stanley Martin Cohen. . (2016) Hepatitis C Management in Patients with Hepatitis C and HIV Co-infection. Current Hepatology Reports 15:3, 158-166. CrossRef

  • 37

    Tarik Asselah, Christophe Hézode, Roula B Qaqish, Magdy ElKhashab, Tarek Hassanein, George Papatheodoridis, Jordan J Feld, Christophe Moreno, Stefan Zeuzem, Peter Ferenci, Yao Yu, Rebecca Redman, Tami Pilot-Matias, Niloufar Mobashery. . (2016) Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. The Lancet Gastroenterology & Hepatology 1:1, 25-35. CrossRef

  • 38

    Antonio Craxì, Carlo Federico Perno, Mauro Viganò, Francesca Ceccherini-Silberstein, Salvatore Petta. . (2016) From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 48:9, 995-1005. CrossRef

  • 39

    Akshanth R. Polepally, Sven Mensing, Amit Khatri, Denise Beck, Wei Liu, Walid M. Awni, Rajeev M. Menon, Sandeep Dutta. . (2016) Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clinical Pharmacokinetics 55:9, 1091-1101. CrossRef

  • 40

    George N. Ioannou, Lauren A. Beste, Michael F. Chang, Pamela K. Green, Elliott Lowy, Judith I. Tsui, Feng Su, Kristin Berry. . (2016) Effectiveness of Sofosbuvir, LedipasvirSofosbuvir, or ParitaprevirRitonavirOmbitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology 151:3, 457-471.e5. CrossRef

  • 41

    Masao Omata, Tatsuo Kanda, Lai Wei, Ming-Lung Yu, Wang-Long Chuang, Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Jose Sollano, Manoj Kumar, Ankur Jindal, Barjesh Chander Sharma, Saeed S. Hamid, A. Kadir Dokmeci, Mamun-Al-Mahtab, Geofferey W. McCaughan, Jafri Wasim, Darrell H. G. Crawford, Jia-Horng Kao, Osamu Yokosuka, George K. K. Lau, Shiv Kumar Sarin. . (2016) ASL consensus statements and recommendation on treatment of hepatitis C. Hepatology International 10:5, 702-726. CrossRef

  • 42

    Masao Omata, Tatsuo Kanda, Lai Wei, Ming-Lung Yu, Wang-Long Chuang, Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Jose Sollano, Manoj Kumar, Ankur Jindal, Barjesh Chander Sharma, Saeed S. Hamid, A. Kadir Dokmeci, Mamun Al-Mahtab, Geofferey W. McCaughan, Jafri Wasim, Darrell H. G. Crawford, Jia-Horng Kao, Osamu Yokosuka, George K. K. Lau, Shiv Kumar Sarin. . (2016) ASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatology International 10:5, 681-701. CrossRef

  • 43

    Claudia Hawkins, Jennifer Grant, Lauren Rose Ammerman, Frank Palella, Milena Mclaughlin, Richard Green, Donna Mcgregor, Valentina Stosor. . (2016) High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIVHCV-coinfected patients: a real-world perspective. Journal of Antimicrobial Chemotherapy 71:9, 2642-2645. CrossRef

  • 44

    (2016) EASL Recommendations on Treatment of Hepatitis C 2016. Journal of Hepatology. CrossRef

  • 45

    Jordan J. Feld, Ira M. Jacobson, Mark S. Sulkowski, Fred Poordad, Fernando Tatsch, Jean-Michel Pawlotsky. . (2016) Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver International. CrossRef

  • 46

    R. Flisiak, E. Janczewska, M. Wawrzynowicz-Syczewska, J. Jaroszewicz, D. Zarębska-Michaluk, K. Nazzal, B. Bolewska, J. Bialkowska, H. Berak, K. Fleischer-Stępniewska, K. Tomasiewicz, K. Karwowska, K. Rostkowska, A. Piekarska, O. Tronina, G. Madej, A. Garlicki, M. Lucejko, A. Pisula, E. Karpińska, W. Kryczka, A. Wiercińska-Drapało, I. Mozer-Lisewska, M. Jabłkowski, A. Horban, B. Knysz, M. Tudrujek, W. Halota, K. Simon. . (2016) Real-world effectiveness and safety of ombitasvirparitaprevirritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Alimentary Pharmacology & Therapeutics. CrossRef

  • 47

    Sern Wei Yeoh. . (2016) Iatrogenic Cushing Syndrome from Interaction Between Ritonavir and Oral Budesonide During Direct Acting Antiviral Hepatitis C Therapy. Journal of Clinical and Experimental Hepatology 6:3, 246-249. CrossRef

  • 48

    Nicholas A. Meanwell. . (2016) 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. Journal of Medicinal Chemistry 59:16, 7311-7351. CrossRef

  • 49

    Sammy Saab, Hélène Parisé, Suchin Virabhak, Alice Wang, Steven E. Marx, Yuri Sanchez Gonzalez, Derek Misurski, Scott Johnson. . (2016) Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US. Journal of Medical Economics 19:8, 795-805. CrossRef

  • 50

    Akshanth R. Polepally, Jennifer R. King, Bifeng Ding, Diana L. Shuster, Emily O. Dumas, Amit Khatri, Yi-Lin Chiu, Thomas J. Podsadecki, Rajeev M. Menon. . (2016) Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, ParitaprevirRitonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers. Clinical Pharmacokinetics 55:8, 1003-1014. CrossRef

  • 51

    L. I. Backus, P. S. Belperio, T. A. Shahoumian, T. P. Loomis, L. A. Mole. . (2016) Comparative effectiveness of ledipasvirsofosbuvir ± ribavirin vs. ombitasvirparitaprevirritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. Alimentary Pharmacology & Therapeutics 44:4, 400-410. CrossRef

  • 52

    Fasiha Kanwal, Jennifer R. Kramer, Hashem B. El-Serag, Susan Frayne, Jack Clark, Yumei Cao, Thomas Taylor, Donna Smith, Donna White, Steven M. Asch. . (2016) Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. Clinical Infectious Diseases 63:3, 291-299. CrossRef

  • 53

    H. Mo, C. Hedskog, E. Svarovskaia, S.-C. Sun, I. M. Jacobson, D. M. Brainard, J. G. McHutchison, M. D. Miller. . (2016) Antiviral response and resistance analysis of treatment-naïve HCV-infected patients receiving single and multiple doses of GS-9190. Journal of Viral Hepatitis 23:8, 644-651. CrossRef

  • 54

    Andrea Marcellusi, Raffaella Viti, Francesco Damele, Calogero Cammà, Gloria Taliani, Francesco Saverio Mennini. . (2016) Early Treatment in HCV: Is it a Cost-Utility Option from the Italian Perspective?. Clinical Drug Investigation 36:8, 661-672. CrossRef

  • 55

    Eric Lawitz, Gary Matusow, Edwin DeJesus, Eric M. Yoshida, Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert W. Herring, Gary Poleynard, Aasim Sheikh, Hillel Tobias, Marcelo Kugelmas, Ronald Kalmeijer, Monika Peeters, Oliver Lenz, Bart Fevery, Guy De La Rosa, Jane Scott, Rekha Sinha, James Witek. . (2016) Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 64:2, 360-369. CrossRef

  • 56

    Michael Charlton, Travis Dick. . 2016. Hepatitis C. Practical Gastroenterology and Hepatology Board Review Toolkit, 480-486. CrossRef

  • 57

    Leah C. Jimmerson, Thomas J. Urban, Aimee Truesdale, Fafa Baouchi-Mokrane, Shyam Kottilil, Eric G. Meissner, Zayani Sims, Jacob A. Langness, Ariel Hodara, Christina L. Aquilante, Jennifer J. Kiser. . (2016) Variant Inosine Triphosphatase Phenotypes Are Associated With reased Ribavirin Triphosphate Levels. The Journal of Clinical Pharmacology. CrossRef

  • 58

    Zobair M. Younossi, Maria Stepanova, Masao Omata, Masashi Mizokami, Mercedes Walters, Sharon Hunt. . (2016) Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine 95:33, e4243. CrossRef

  • 59

    David L. Wyles, Mark S. Sulkowski, Douglas Dieterich. . (2016) Management of Hepatitis CHIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy: Table 1.. Clinical Infectious Diseases 63:suppl 1, S3-S11. CrossRef

  • 60

    Amit Khatri, Sandeep Dutta, Thomas C. Marbury, Richard A. Preston, Lino Rodrigues, Haoyu Wang, Walid M. Awni, Rajeev M. Menon. . (2016) Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment. Clinical Pharmacokinetics. CrossRef

  • 61

    Rena K. Fox, Thiruvengadam Muniraj. . (2016) Pharmacologic Therapies in Gastrointestinal Diseases. Medical Clinics of North America 100:4, 827-850. CrossRef

  • 62

    Akshanth R. Polepally, Sandeep Dutta, Beibei Hu, Thomas J. Podsadecki, Walid M. Awni, Rajeev M. Menon. . (2016) Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents ParitaprevirRitonavir and Ombitasvir With and Without Dasabuvir. Clinical Pharmacology in Drug Development 5:4, 269-277. CrossRef

  • 63

    E. G. Meissner, A. Kohli, K. Virtaneva, D. Sturdevant, C. Martens, S. F. Porcella, J. G. McHutchison, H. Masur, S. Kottilil. . (2016) Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. Journal of Viral Hepatitis 23:7, 496-505. CrossRef

  • 64

    Elise J. Smolders, Clara T. M. M. de Kanter, Bart van Hoek, Joop E. Arends, Joost P. H. Drenth, David M. Burger. . (2016) Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver andor Renal Impairment. Drug Safety 39:7, 589-611. CrossRef

  • 65

    Vito Di Marco, Vincenza Calvaruso, Donatella Ferraro, Maria Grazia Bavetta, Giuseppe Cabibbo, Elisabetta Conte, Calogero Cammà, Stefania Grimaudo, Rosaria Maria Pipitone, Fabio Simone, Sergio Peralta, Andrea Arini, Antonio Craxì. . (2016) Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension. Gastroenterology 151:1, 130-139.e2. CrossRef

  • 66

    Jia-Horng Kao, Donald M. Jensen, Michael P. Manns, Ira Jacobson, Hiromitsu Kumada, Joji Toyota, Jeong Heo, Boris Yoffe, William Sievert, Fernando Bessone, Cheng-Yuan Peng, Stuart K. Roberts, Youn-Jae Lee, Rafia Bhore, Patricia Mendez, Eric Hughes, Stephanie Noviello. . (2016) Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver International 36:7, 954-962. CrossRef

  • 67

    Claudia Fabrizio, Annalisa Saracino, Michele Milella, Francesco Resta, Gioacchino Angarano. . (2016) Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevirritonavir, ombitasvir, dasabuvir and ribavirin. International Journal of Antimicrobial Agents 48:1, 115-116. CrossRef

  • 68

    Mark W. Hull, Eric M. Yoshida, Julio S. G. Montaner. . (2016) Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. Current Infectious Disease Reports 18:7. CrossRef

  • 69

    Karla Thornton, Paulina Deming, Richard A. Manch, Ann Moore, Anita Kohli, Robert Gish, Norman L. Sussman, Saira Khaderi, John Scott, Jorge Mera, Terry Box, Clifford Qualls, Miranda Sedillo, Sanjeev Arora. . (2016) Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment. Hepatology International 10:4, 624-631. CrossRef

  • 70

    M. L. Witkop, K. Peerlinck, B. A. Luxon. . (2016) Medical co-morbidities of patients with haemophilia: pain, obesity and hepatitis C. Haemophilia 22, 47-53. CrossRef

  • 71

    Zobair M. Younossi, Maria Stepanova, Jordan Feld, Stefan Zeuzem, Ira Jacobson, Kosh Agarwal, Christophe Hezode, Fatema Nader, Linda Henry, Sharon Hunt. . (2016) Sofosbuvirvelpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. Journal of Hepatology 65:1, 33-39. CrossRef

  • 72

    Shruti H. Mehta, David L. Thomas. . (2016) Doing the math on hepatitis C virus treatment. Journal of Hepatology 65:1, 5-6. CrossRef

  • 73

    J. Shen, M. Serby, B. Surber, A. J. Lee, J. Ma, P. Badri, R. Menon, O. Kavetskaia, S. M. de Morais, J. Sydor, V. Fischer. . (2016) Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans. Drug Metabolism and Disposition 44:8, 1148-1157. CrossRef

  • 74

    Sathej M. Gopalakrishnan, Akshanth R. Polepally, Sven Mensing, Amit Khatri, Rajeev M. Menon. . (2016) Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection. Clinical Pharmacokinetics. CrossRef

  • 75

    David Del Bello, Agnes Cha, Maria Sorbera, Kian Bichoupan, Calley Levine, Erin Doyle, Alyson Harty, Neal Patel, Michel Ng, Donald Gardenier, Joseph Odin, Thomas D. Schiano, Daniel S. Fierer, Leonard Berkowitz, Ponni V. Perumalswami, Douglas T. Dieterich, Andrea D. Branch. . (2016) Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV. Clinical Infectious Diseases 62:12, 1497-1504. CrossRef

  • 76

    Laura Benítez-Gutiérrez, Pablo Barreiro, Pablo Labarga, Carmen de Mendoza, José V. Fernandez-Montero, Ana Arias, José M. Peña, Vicente Soriano. . (2016) Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opinion on Pharmacotherapy 17:9, 1215-1223. CrossRef

  • 77

    A. Majumdar, M. T. Kitson, S. K. Roberts. . (2016) Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Alimentary Pharmacology & Therapeutics 43:12, 1276-1292. CrossRef

  • 78

    (2016) Experimental and Clinical Transplantation 14:3. CrossRef

  • 79

    Adriaan J van der Meer, Raoel Maan, Bart J Veldt, Jordan J Feld, Heiner Wedemeyer, Jean-François Dufour, Frank Lammert, Andres Duarte-Rojo, Michael P Manns, Stefan Zeuzem, W Peter Hofmann, Robert J de Knegt, Bettina E Hansen, Harry LA Janssen. . (2016) Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. Journal of Gastroenterology and Hepatology 31:6, 1168-1176. CrossRef

  • 80

    Mitchell L Shiffman, Vinod Rustgi, Michael Bennett, Xavier Forns, Tarik Asselah, Ramon Planas Vila, Li Liu, Marcos Pedrosa, Jonathan Moller, Nancy Reau. . (2016) Safety and Efficacy of OmbitasvirParitaprevirRitonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. The American Journal of Gastroenterology 111:6, 845-851. CrossRef

  • 81

    Jeanne-Marie Giard, Norah A. Terrault. . (2016) Women with Cirrhosis. Gastroenterology Clinics of North America 45:2, 345-358. CrossRef

  • 82

    Reinhart Zachoval, Maria-Christina Jung. . (2016) Aktuelle Therapieoptionen bei chronischer Hepatitis C. MMW - Fortschritte der Medizin 158:S2, 54-58. CrossRef

  • 83

    Alexis P. Chidi, Cindy L. Bryce, Julie M. Donohue, Michael J. Fine, Douglas P. Landsittel, Larissa Myaskovsky, Shari S. Rogal, Galen E. Switzer, Allan Tsung, Kenneth J. Smith. . (2016) Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value in Health 19:4, 326-334. CrossRef

  • 84

    Paul J. Pockros, K. Rajender Reddy, Parvez S. Mantry, Eric Cohen, Michael Bennett, Mark S. Sulkowski, David E. Bernstein, Daniel E. Cohen, Nancy S. Shulman, Deli Wang, Amit Khatri, Manal Abunimeh, Thomas Podsadecki, Eric Lawitz. . (2016) Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. Gastroenterology 150:7, 1590-1598. CrossRef

  • 85

    Graham R. Foster, William L. Irving, Michelle C.M. Cheung, Alex J. Walker, Benjamin E. Hudson, Suman Verma, John McLauchlan, David J. Mutimer, Ashley Brown, William T.H. Gelson, Douglas C. MacDonald, Kosh Agarwal. . (2016) Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology 64:6, 1224-1231. CrossRef

  • 86

    Mariusz Łucejko, Anna Parfieniuk-Kowerda, Robert Flisiak. . (2016) Ombitasvirparitaprevirritonavir plus dasabuvir combination in the treatment of chronic HCV infection. Expert Opinion on Pharmacotherapy 17:8, 1153-1164. CrossRef

  • 87

    Matthias Götte, Jordan J. Feld. . (2016) Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nature Reviews Gastroenterology & Hepatology 13:6, 338-351. CrossRef

  • 88

    Laura-Patricia Llovet, Sergio Rodríguez-Tajes, María-Carlota Londoño. . (2016) Tratamiento de la hepatitis C en el pre- y postrasplante hepático. Gastroenterología y Hepatología 39, 344-351. CrossRef

  • 89

    R. M. Menon, C. E. Klein, T. J. Podsadecki, Y.-L. Chiu, S. Dutta, W. M. Awni. . (2016) Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. British Journal of Clinical Pharmacology 81:10.1111bcp.v81.5, 929-940. CrossRef

  • 90

    Laura-Patricia Llovet, Sergio Rodríguez-Tajes, María-Carlota Londoño. . (2016) Treatment of hepatitis C before and after liver transplantation. Gastroenterología y Hepatología (English Edition) 39:5, 344-351. CrossRef

  • 91

    Thierno Diatta, Delphine Chavade, Françoise Degos, Anne d’Andon, Loïc Guillevin. . (2016) Infection par le virus de l’hépatite C : prise en charge thérapeutique. La Presse Médicale 45:5, 495-508. CrossRef

  • 92

    Amit Khatri, Sandeep Dutta, Haoyu Wang, Thomas Podsadecki, Roger Trinh, Walid Awni, Rajeev Menon. . (2016) Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, ParitaprevirRitonavir, and Dasabuvir and HIV-1 Protease Inhibitors. Clinical Infectious Diseases 62, 972-979. CrossRef

  • 93

    Martin Lagging, Rune Wejstål, Gunnar Norkrans, Olle Karlström, Soo Aleman, Ola Weiland, Maria Castedal, Filip Josephson, . . (2016) Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. Infectious Diseases 48, 251-261. CrossRef

  • 94

    N. Gamal, P. Andreone. . (2016) Safety and efficacy of once daily ledipasvirsofosbuvir fixed-dose combination in patients with chronic hepatitis C. Expert Opinion on Drug Safety 15, 549-557. CrossRef

  • 95

    Sahar Saeed, Erin C. Strumpf, Sharon L. Walmsley, Kathleen Rollet-Kurhajec, Neora Pick, Valerie Martel-Laferrière, Mark Hull, M. John Gill, Joseph Cox, Curtis Cooper, Marina B. Klein. . (2016) How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIVHCV in the Real World?. Clinical Infectious Diseases 62, 919-926. CrossRef

  • 96

    Nancy Reau, Michael W. Fried, David R. Nelson, Robert S. Brown, Gregory T. Everson, Stuart C. Gordon, Ira M. Jacobson, Joseph K. Lim, Paul J. Pockros, K. Rajender Reddy, Kenneth E. Sherman. . (2016) HCV Council - critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. Liver International 36:10.1111liv.2016.36.issue-4, 488-502. CrossRef

  • 97

    Donald M. Jensen, Michael Brunda, Robert Elston, Edward J. Gane, Jacob George, Katerina Glavini, Janet M. Hammond, Sophie Le Pogam, Isabel Nájera, Sharon Passe, Anna Piekarska, Ignacio Rodriguez, Stefan Zeuzem, Tom Chu, . . (2016) Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver International 36:10.1111liv.2016.36.issue-4, 505-514. CrossRef

  • 98

    Anthony Cousien, Viet Chi Tran, Sylvie Deuffic-Burban, Marie Jauffret-Roustide, Jean-Stéphane Dhersin, Yazdan Yazdanpanah. . (2016) Hepatitis C treatment as prevention of viral transmission and liver-related morbidity in persons who inject drugs. Hepatology 63:10.1002hep.v63.4, 1090-1101. CrossRef

  • 99

    Barbara Testoni, David Durantel, Fanny Lebossé, Judith Fresquet, François Helle, Francesco Negro, Maria Francesca Donato, Massimo Levrero, Fabien Zoulim. . (2016) Ribavirin restores IFNα responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut 65, 672-682. CrossRef

  • 100

    Sabrina Bagaglio, Andrea Andolina, Marco Merli, Caterina Uberti-Foppa, Giulia Morsica. . (2016) Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. Viruses 8, 91. CrossRef

  • 101

    Kate Childs, Chris Taylor, Douglas Dieterich, Kosh Agarwal. . (2016) Directly acting antivirals for hepatitis C virus arrive in HIVhepatitis C virus co-infected patients. AIDS 30, 975-989. CrossRef

  • 102

    J. Cabezas, S. Llerena, S. Menéndez, C. Alonso Martín, J. Crespo García. . (2016) Hepatitis por el virus C. Medicine - Programa de Formación Médica Continuada Acreditado 12:9, 484-493. CrossRef

  • 103

    Liana Fraenkel, Joseph Lim, Guadalupe Garcia-Tsao, Valerie Reyna, Alexander Monto. . (2016) Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis. Journal of Clinical Gastroenterology 50, 252-257. CrossRef

  • 104

    V. C. Di Maio, V. Cento, D. Di Paolo, M. Aragri, F. De Leonardis, M. Tontodonati, V. Micheli, M. C. Bellocchi, F. P. Antonucci, A. Bertoli, I. Lenci, M. Milana, L. Gianserra, M. Melis, A. Di Biagio, C. Sarrecchia, L. Sarmati, S. Landonio, S. Francioso, L. Lambiase, L. A. Nicolini, S. Marenco, L. Nosotti, V. Giannelli, M. Siciliano, D. Romagnoli, A. Pellicelli, J. Vecchiet, C. F. Magni, S. Babudieri, M. S. Mura, G. Taliani, C. Mastroianni, U. Vespasiani-Gentilucci, M. Romano, F. Morisco, A. Gasbarrini, V. Vullo, S. Bruno, C. Baiguera, C. Pasquazzi, G. Tisone, A. Picciotto, M. Andreoni, G. Parruti, G. Rizzardini, M. Angelico, C. F. Perno, F. Ceccherini-Silberstein. . (2016) HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. Journal of Antimicrobial Chemotherapy 71, 739-750. CrossRef

  • 105

    D. Banerjee, K. R. Reddy. . (2016) Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Alimentary Pharmacology & Therapeutics 43:10.1111apt.2016.43.issue-6, 674-696. CrossRef

  • 106

    Prajakta S. Badri, Jennifer R. King, Akshanth R. Polepally, Barbara H. McGovern, Sandeep Dutta, Rajeev M. Menon. . (2016) Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy. Clinical Pharmacokinetics 55, 275-295. CrossRef

  • 107

    Whitney E. Jackson, Elizabeth C. Verna. . (2016) Does SVR Prevent Transplant in HCV?. Current Hepatology Reports 15, 44-52. CrossRef

  • 108

    Tess Petersen, Kerry Townsend, Lori A. Gordon, Sreetha Sidharthan, Rachel Silk, Amy Nelson, Chloe Gross, Monica Calderón, Michael Proschan, Anu Osinusi, Michael A. Polis, Henry Masur, Shyam Kottilil, Anita Kohli. . (2016) High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study. Hepatology International 10, 310-319. CrossRef

  • 109

    Yutaka Kishida, Naohiko Imaizumi, Hirohisa Tanimura, Shinichiro Kashiwamura, Toru Kashiwagi. . (2016) A Protease Inhibitor with Induction Therapy with Natural Interferon-β in Patients with HCV Genotype 1b Infection. International Journal of Molecular Sciences 17, 350. CrossRef

  • 110

    (2016) KASL clinical practice guidelines: management of hepatitis C. Clinical and Molecular Hepatology 22, 76-139. CrossRef

  • 111

    Eleanor M. Wilson, Sarah Kattakuzhy, Sreetha Sidharthan, Zayani Sims, Lydia Tang, Mary McLaughlin, Angie Price, Amy Nelson, Rachel Silk, Chloe Gross, Elizabeth Akoth, Hongmei Mo, G. Mani Subramanian, Phillip S. Pang, John G. McHutchison, Anu Osinusi, Henry Masur, Anita Kohli, Shyam Kottilil. . (2016) Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens. Clinical Infectious Diseases 62, 280-288. CrossRef

  • 112

    Alexis P. Chidi, Shari Rogal, Cindy L. Bryce, Michael J. Fine, Chester B. Good, Larissa Myaskovsky, Vinod K. Rustgi, Allan Tsung, Kenneth J. Smith. . (2016) Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C. Hepatology 63:10.1002hep.v63.2, 428-436. CrossRef

  • 113

    Parvez S. Mantry, Lakshmikant Pathak. . (2016) Dasabuvir (ABT333) for the treatment of chronic HCV genotype I: a new face of cure, an expert review. Expert Review of Anti-infective Therapy 14, 157-165. CrossRef

  • 114

    Paulina Deming, Michelle T. Martin, Juliana Chan, Thomas J. Dilworth, Rania El-Lababidi, Bryan L. Love, Rima A. Mohammad, Amy Nguyen, Linda M. Spooner, Suzanne B. Wortman. . (2016) Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36:10.1002phar.2016.36.issue-2, 203-217. CrossRef

  • 115

    LS Wu, LC Jimmerson, CE MacBrayne, JJ Kiser, DZ D'Argenio. . (2016) Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. CPT: Pharmacometrics & Systems Pharmacology 5:10.1002psp4.v5.2, 65-73. CrossRef

  • 116

    Sean M. McConachie, Sheila M. Wilhelm, Pramodini B. Kale-Pradhan. . (2016) New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Review of Clinical Pharmacology 9, 287-302. CrossRef

  • 117

    J. F. Waring, E. O. Dumas, S. Abel, E. Coakley, D. E. Cohen, J. Wade Davis, T. Podsadecki, S. Dutta. . (2016) Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevirR with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects. Journal of Viral Hepatitis 23:2, 96-104. CrossRef

  • 118

    (2016) EASL Clinical Practice Guidelines: Liver transplantation. Journal of Hepatology 64:2, 433-485. CrossRef

  • 119

    Jordan J. Feld, Christophe Moreno, Roger Trinh, Edward Tam, Stefan Bourgeois, Yves Horsmans, Magdy Elkhashab, David E. Bernstein, Ziad Younes, Robert W. Reindollar, Lois Larsen, Bo Fu, Kevin Howieson, Akshanth R. Polepally, Andreas Pangerl, Nancy S. Shulman, Fred Poordad. . (2016) Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvirparitaprevirr and dasabuvir for 12weeks. Journal of Hepatology 64:2, 301-307. CrossRef

  • 120

    Audrey Coilly, Bruno Roche, Jean- Charles Duclos-Vallée, Didier Samuel. . (2016) News and challenges in the treatment of hepatitis C in liver transplantation. Liver International 36:10.1111liv.2016.36.issue-S1, 34-42. CrossRef

  • 121

    Tarik Asselah, Nathalie Boyer, David Saadoun, Michele Martinot-Peignoux, Patrick Marcellin. . (2016) Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver International 36:10.1111liv.2016.36.issue-S1, 47-57. CrossRef

  • 122

    Sven Mensing, Akshanth R. Polepally, Denise König, Amit Khatri, Wei Liu, Thomas J. Podsadecki, Walid M. Awni, Rajeev M. Menon, Sandeep Dutta. . (2016) Population Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b2 Studies. The AAPS Journal 18, 270-280. CrossRef

  • 123

    Allison Mah, Alissa Wright. . (2016) Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. Current Infectious Disease Reports 18. CrossRef

  • 124

    (2016) Experimental and Clinical Transplantation 14:1. CrossRef

  • 125

    Geum-Youn Gwak. . (2016) Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Patients with Decompensated Cirrhosis. The Korean Journal of Gastroenterology 67, 137. CrossRef

  • 126

    Sang Hoon Park. . (2016) Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1. The Korean Journal of Gastroenterology 67, 127. CrossRef

  • 127

    S. M. Goring, P. Gustafson, Y. Liu, S. Saab, S. K. Cline, R. W. Platt. . (2016) Disconnected by design: analytic approach in treatment networks having no common comparator. Research Synthesis Methods. CrossRef

  • 128

    Akshanth R. Polepally, Prajakta S. Badri, Doerthe Eckert, Sven Mensing, Rajeev M. Menon. . (2016) Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection. European Journal of Drug Metabolism and Pharmacokinetics. CrossRef

  • 129

    Nicolas Goossens, Sophie Clément, Francesco Negro. . 2016. Management of HCV Infection. Handbook of Hepatitis C, 61-78. CrossRef

  • 130

    Allison M. Bell, Jamie L. Wagner, Katie E. Barber, Kayla R. Stover. . (2016) ElbasvirGrazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. International Journal of Hepatology 2016, 1-8. CrossRef

  • 131

    Akihiro Tamori, Masaru Enomoto, Norifumi Kawada. . (2016) Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation 2016, 1-11. CrossRef

  • 132

    Madelyne Bean, Lydia Tang, Shyam Kottilil, Kimberly L. Beavers, Eric G. Meissner. . (2016) On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series. Case Reports in Infectious Diseases 2016, 1-4. CrossRef

  • 133

    Christophe Hézode, Jean-Pierre Bronowicki. . (2016) Ideal oral combinations to eradicate HCV: The role of ribavirin. Journal of Hepatology 64:1, 215-225. CrossRef

  • 134

    Gregory J. Dore, Brian Conway, Yan Luo, Ewa Janczewska, Brygida Knysz, Yan Liu, Adrian Streinu-Cercel, Florin Alexandru Caruntu, Manuela Curescu, Richard Skoien, Wayne Ghesquiere, Włodzimierz Mazur, Alejandro Soza, Francisco Fuster, Susan Greenbloom, Adriana Motoc, Victoria Arama, David Shaw, Istvan Tornai, Joseph Sasadeusz, Olav Dalgard, Danielle Sullivan, Xuan Liu, Mudra Kapoor, Andrew Campbell, Thomas Podsadecki. . (2016) Efficacy and safety of ombitasvirparitaprevirr and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-III trials. Journal of Hepatology 64:1, 19-28. CrossRef

  • 135

    Selena M. Sagan, Benoit Dupont, Jason Grebely, Mel Krajden, Sonya A. MacParland, Jennifer F. Raven, Sahar Saeed, Jordan J. Feld, D. Lorne Tyrrell, Joyce A. Wilson. . (2016) Highlights of the Fourth Canadian Symposium on Hepatitis C: Moving towards a National Action Plan. Canadian Journal of Gastroenterology and Hepatology 2016, 1-11. CrossRef

  • 136

    Mark Hull, Stephen Shafran, Alex Wong, Alice Tseng, Pierre Giguère, Lisa Barrett, Shariq Haider, Brian Conway, Marina Klein, Curtis Cooper. . (2016) CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIVHepatitis C Adult Guidelines for Management and Treatment. Canadian Journal of Infectious Diseases and Medical Microbiology 2016, 1-34. CrossRef

  • 137

    Santiago J. Munoz, Kenneth D. Rothstein, Alexandra L. Gibas. . 2016. Hepatitis C Virus Infection: A New Era. Contemporary Liver Transplantation, 1-8. CrossRef

  • 138

    Cecilia Trucchi, Andrea Orsi, Cristiano Alicino, Laura Sticchi, Giancarlo Icardi, Filippo Ansaldi. . (2016) State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. Journal of Immunology Research 2016, 1-19. CrossRef

  • 139

    Nicolas Tremblay, Alex Young Park, Daniel Lamarre. . 2016. HCV NS34A Protease Inhibitors and the Road to Effective Direct-Acting Antiviral Therapies. Hepatitis C Virus II, 257-285. CrossRef

  • 140

    Elaine Y Cheng, Sammy Saab, Curtis D Holt, Ronald W Busuttil. . (2015) Paritaprevirritonavirombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection. Expert Opinion on Pharmacotherapy 16, 2835-2848. CrossRef

  • 141

    Stéphan Clémençon, Anthony Cousien, Miraine Dávila Felipe, Viet Chi Tran. . (2015) On computer-intensive simulation and estimation methods for rare-event analysis in epidemic models. Statistics in Medicine 34:10.1002sim.v34.28, 3696-3713. CrossRef

  • 142

    Marc Bourlière, Xavier Adhoute, Christelle Ansaldi, Valérie Oules, Souad Benali, Isabelle Portal, Paul Castellani, Philippe Halfon. . (2015) Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection. Expert Review of Gastroenterology & Hepatology 9, 1483-1494. CrossRef

  • 143

    Prarthana Thiagarajan, Stephen D. Ryder. . (2015) The hepatitis C revolution part 2. Current Opinion in Infectious Diseases 28, 572-575. CrossRef

  • 144

    Maria Buti, Mar Riveiro-Barciela, Rafael Esteban. . (2015) Management of direct-acting antiviral agent failures. Journal of Hepatology 63, 1511-1522. CrossRef

  • 145

    Marc Bourlière, Tarik Asselah. . (2015) HCV Genotype 1 Infection: IFN-Free Treatment with Direct-Acting Antivirals Available in 2015. Current Hepatology Reports 14, 260-266. CrossRef

  • 146

    B. Raziorrouh, N. Grüner. . (2015) Hepatitis C — Therapie-Update. CME 12, 7-16. CrossRef

  • 147

    Clarissa Freissmuth, Peter Ferenci, Harald Hofer. . (2015) Therapie der Hepatitis C Virusinfektion. Wiener klinische Wochenschrift Education 10, 61-72. CrossRef

  • 148

    Paul Kwo, Saurabh Agrawal. . (2015) Treating hepatitis C virus in patients with decompensated cirrhosis: Why is it so difficult and does a sustained response rate rescue the patient from liver transplantation?. Clinical Liver Disease 6:10.1002cld.v6.6, 133-135. CrossRef

  • 149

    Manuela G. Neuman, Stephen Malnick, Yaakov Maor, Radu M. Nanau, Ehud Melzer, Peter Ferenci, Helmut K. Seitz, Sebastian Mueller, Haim Mell, Didier Samuel, Lawrence B. Cohen, Kusum K. Kharbanda, Natalia A. Osna, Murali Ganesan, Kyle J. Thompson, Iain H. McKillop, Abraham Bautista, Ramon Bataller, Samuel W. French. . (2015) Alcoholic liver disease: Clinical and translational research. Experimental and Molecular Pathology 99:3, 596-610. CrossRef

  • 150

    Saleh Alqahtani, Mark Sulkowski. . (2015) Current and Evolving Treatments of Genotype 1 Hepatitis C Virus. Gastroenterology Clinics of North America 44:4, 825-843. CrossRef

  • 151

    Georg Dultz, Stefan Zeuzem. . (2015) Hepatitis C Virus. Gastroenterology Clinics of North America 44:4, 807-824. CrossRef

  • 152

    Jennifer Ann Kieran, Suzanne Norris, Aisling O’Leary, Cathal Walsh, Raphael Merriman, D. Houlihan, P. Aiden McCormick, Susan McKiernan, Colm Bergin, Michael Barry. . (2015) Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. BMC Infectious Diseases 15:1. CrossRef

  • 153

    Andrea Gori, Manuela Doroana, Oksana Chernova, Jürgen K. Rockstroh, Denes Banhegyi, Colm Bergin, Gabriella Verucchi, Chris Liu, Ralph DeMasi, Blanca Hadacek, Mark Nelson. . (2015) Telaprevir-based therapy for treatment of HIV-1 and hepatitis C virus co-infected patients: An early access programme. Journal of Infection 71:6, 675-682. CrossRef

  • 154

    Dan Smyth, Duncan Webster. . (2015) Hepatitis C: pay now or pay later?. Future Virology 10:12, 1285-1290. CrossRef

  • 155

    David Del Bello, Fanny Ita-Nagy, Jonathan Hand, Douglas Dieterich. . (2015) Treatment of hepatitis C in coinfected patients. Future Virology 10:12, 1291-1305. CrossRef

  • 156

    Elisabetta Degasperi, Alessio Aghemo, Massimo Colombo. . (2015) Daclatasvir for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy 16, 2679-2688. CrossRef

  • 157

    Michael A Smith, Bryan L Love, Rima A Mohammad. . (2015) The changing landscape of adverse drug events associated with chronic hepatitis C virus therapy. Expert Opinion on Drug Safety 14, 1649-1652. CrossRef

  • 158

    Syed-Mohammed Jafri, Stuart C. Gordon. . (2015) The safety of daclatasvir for the treatment of hepatitis C. Expert Opinion on Drug Safety 14, 1787-1797. CrossRef

  • 159

    Martin Bonacci, Maria-Carlota Londoño, Nuria Esforzado, Xavier Forns, Jose-Miguel Sotoca, Josep-Maria Campistol. . (2015) Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list. Transplant International 28:10.1111tri.2015.28.issue-11, 1345-1349. CrossRef

  • 160

    J. A. Gutierrez, E. J. Lawitz, F. Poordad. . (2015) Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. Journal of Viral Hepatitis 22, 861-870. CrossRef

  • 161

    Raoel Maan, Robert J. de Knegt, Bart J. Veldt. . (2015) Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. Drugs 75, 1981-1992. CrossRef

  • 162

    Xavier Forns, Fred Poordad, Marcos Pedrosa, Marina Berenguer, Heiner Wedemeyer, Peter Ferenci, Mitchell L. Shiffman, Michael W. Fried, Sandra Lovell, Roger Trinh, Juan Carlos Lopez-Talavera, Gregory Everson. . (2015) Ombitasvirparitaprevirr, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Liver International 35, 2358-2362. CrossRef

  • 163

    Fabien Zoulim, T Jake Liang, Alexander L Gerbes, Alessio Aghemo, Sylvie Deuffic-Burban, Geoffrey Dusheiko, Michael W Fried, Stanislas Pol, Jürgen Kurt Rockstroh, Norah A Terrault, Stefan Wiktor. . (2015) Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1. Gut 64, 1824-1833. CrossRef

  • 164

    David R. Walker, Marcos C. Pedrosa, Shivaji R. Manthena, Nikil Patel, Steven E. Marx. . (2015) Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV). Advances in Therapy 32, 1117-1127. CrossRef

  • 165

    Zobair M. Younossi. . (2015) The price of shortening anti-hepatitis C virus therapy: Is this truly cost saving?. Clinical Liver Disease 6, 126-128. CrossRef

  • 166

    Erik Lontok, Patrick Harrington, Anita Howe, Tara Kieffer, Johan Lennerstrand, Oliver Lenz, Fiona McPhee, Hongmei Mo, Neil Parkin, Tami Pilot-Matias, Veronica Miller. . (2015) Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 62, 1623-1632. CrossRef

  • 167

    Andrew J. Muir, Susanna Naggie. . (2015) Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?. Clinical Gastroenterology and Hepatology 13:12, 2166-2172. CrossRef

  • 168

    Paul Y. Kwo. . (2015) Regimens for Cirrhotic Patients. Clinics in Liver Disease 19:4, 657-667. CrossRef

  • 169

    Walid S. Ayoub, Tram T. Tran. . (2015) Regimens for the Hepatitis C Treatment-Naive Patient. Clinics in Liver Disease 19:4, 619-627. CrossRef

  • 170

    Tatyana Kushner, Vandana Khungar. . (2015) Direct-Acting Antiviral Agents. Clinics in Liver Disease 19:4, 629-639. CrossRef

  • 171

    V Schaerer, S Haubitz, H Kovari, B Ledergerber, J Ambrosioni, M Cavassini, M Stoeckle, P Schmid, L Decosterd, M Aouri, J Böni, HF Günthard, H Furrer, KJ Metzner, J Fehr, A Rauch, . . (2015) Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. HIV Medicine 16:10, 599-607. CrossRef

  • 172

    Sarah Kattakuzhy, Eleanor Wilson, Sreetha Sidharthan, Zayani Sims, Mary McLaughlin, Angie Price, Rachel Silk, Chloe Gross, Elizabeth Akoth, Maryellen McManus, Benjamin Emmanuel, Shikha Shrivastava, Lydia Tang, Amy Nelson, Gebeyehu Teferi, Jose Chavez, Brian Lam, Hongmei Mo, Anuoluwapo Osinusi, Michael A. Polis, Henry Masur, Anita Kohli, Shyamasundaran Kottilil. . (2015) Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti–Hepatitis C Virus Therapy in Patients With Advanced Liver Disease. Clinical Infectious Diseases, civ897. CrossRef

  • 173

    Stephen D. Shafran. . (2015) HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. Clinical Infectious Diseases 61, 1127-1134. CrossRef

  • 174

    K. Deterding, C. Höner zu Siederdissen, K. Port, P. Solbach, L. Sollik, J. Kirschner, C. Mix, J. Cornberg, D. Worzala, H. Mix, M. P. Manns, M. Cornberg, H. Wedemeyer. . (2015) Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Alimentary Pharmacology & Therapeutics 42, 889-901. CrossRef

  • 175

    Harita Nyalakonda, Netanya S. Utay. . (2015) A new era of therapy for hepatitis C virus infection. Current Opinion in Infectious Diseases 28, 471-478. CrossRef

  • 176

    Bashar A. Aqel, Surakit Pungpapong, Michael Leise, K. Tuesday Werner, Amy E. Chervenak, Kymberly D. Watt, Jennifer L. Murphy, Kristen Ryland, Andrew P. Keaveny, Ryan McLemore, Hugo E. Vargas. . (2015) Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology 62, 1004-1012. CrossRef

  • 177

    Hiromitsu Kumada, Kazuaki Chayama, Lino Rodrigues, Fumitaka Suzuki, Kenji Ikeda, Hidenori Toyoda, Ken Sato, Yoshiyasu Karino, Yasushi Matsuzaki, Kiyohide Kioka, Carolyn Setze, Tami Pilot-Matias, Meenal Patwardhan, Regis A. Vilchez, Margaret Burroughs, Rebecca Redman. . (2015) Randomized phase 3 trial of ombitasvirparitaprevirritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology 62, 1037-1046. CrossRef

  • 178

    Eric Lawitz, Mihály Makara, Ulus Salih Akarca, Paul J. Thuluvath, Liliana Lucia Preotescu, Peter Varunok, Rosa Mª. Morillas, Coleen Hall, Niloufar Mobashery, Rebecca Redman, Tami Pilot-Matias, Regis A. Vilchez, Christophe Hézode. . (2015) Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Gastroenterology 149:4, 971-980.e1. CrossRef

  • 179

    Peter Ferenci, Karin Kozbial, Mattias Mandorfer, Harald Hofer. . (2015) HCV targeting of patients with cirrhosis. Journal of Hepatology 63:4, 1015-1022. CrossRef

  • 180

    Amit Khatri, Rajeev M. Menon, Thomas C. Marbury, Eric J. Lawitz, Thomas J. Podsadecki, Victoria M. Mullally, Bifeng Ding, Walid M. Awni, Barry M. Bernstein, Sandeep Dutta. . (2015) Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. Journal of Hepatology 63:4, 805-812. CrossRef

  • 181

    Marianne Martinello, Gail V. Matthews. . (2015) Enhancing the detection and management of acute hepatitis C virus infection. International Journal of Drug Policy 26:10, 899-910. CrossRef

  • 182

    Sabela Lens, Diego Rincón, Montserrat García-Retortillo, Agustín Albillos, Jose Luis Calleja, Rafael Bañares, Juan González Abraldes, Jaume Bosch, Jose Maria Sanchez-Tapias, Xavier Forns, Juan Carlos García-Pagán. . (2015) Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. Clinical Gastroenterology and Hepatology 13:10, 1846-1853.e1. CrossRef

  • 183

    Emily L Heil, Lauren M Hynicka, Shyam Kottilil, Lydia Tang. . (2015) What does the pharmacological future of treating chronic hepatitis C look like?. Expert Review of Clinical Pharmacology 8, 605-622. CrossRef

  • 184

    Jerzy Jaroszewicz, Marta Flisiak-Jackiewicz, Dariusz Lebensztejn, Robert Flisiak. . (2015) Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opinion on Investigational Drugs 24, 1229-1239. CrossRef

  • 185

    Zoe Mariño, Sabela Lens, Martina Gambato, Xavier Forns. . (2015) Advances in hepatitis C therapies. Expert Opinion on Pharmacotherapy 16, 1929-1943. CrossRef

  • 186

    Sandra Beinhardt, Markus Peck-Radosavljevic, Harald Hofer, Peter Ferenci. . (2015) Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting. Transplant International 28:10.1111tri.2015.28.issue-9, 1011-1024. CrossRef

  • 187

    Darrick K. Li, Raymond T. Chung. . (2015) Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer 121:10.1002cncr.v121.17, 2874-2882. CrossRef

  • 188

    Valeria Cento, Stephane Chevaliez, Carlo Federico Perno. . (2015) Resistance to direct-acting antiviral agents. Current Opinion in HIV and AIDS 10, 381-389. CrossRef

  • 189

    Adam E. Mikolajczyk, Andrew I. Aronsohn. . (2015) Current Management of Chronic Hepatitis B and C in Chronic Kidney Disease. Advances in Chronic Kidney Disease 22, 352-360. CrossRef

  • 190

    Ashwin Balagopal, David L. Thomas. . (2015) Editorial Commentary : Who is “Special” Now?. Clinical Infectious Diseases 61, 826-828. CrossRef

  • 191

    David Del Bello, Fanny Ita Nagy, Jonathan Hand, Rabea Khedemi, Julien Lécluse-Barth, Douglas Dieterich, Lionel Piroth. . (2015) Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients. Current Opinion in HIV and AIDS 10, 337-347. CrossRef

  • 192

    Lionel Piroth, Hubert Paniez, Anne Marie Taburet, Corine Vincent, Eric Rosenthal, Karine Lacombe, Eric Billaud, David Rey, David Zucman, François Bailly, Jean-Pierre Bronowicki, Mélanie Simony, Alpha Diallo, Jacques Izopet, Jean-Pierre Aboulker, Laurence Meyer, Jean-Michel Molina. . (2015) High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIVHepatitis C Virus Genotype 14 Coinfection: The ANRS HC30 QUADRIH Study. Clinical Infectious Diseases 61, 817-825. CrossRef

  • 193

    Bruno Roche, Audrey Coilly, Anne-Marie Roque-Afonso, Didier Samuel. . (2015) Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance. Viruses 7, 5155-5168. CrossRef

  • 194

    Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, Mohand Ait Ahmed, Setty Allam, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor De Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean-Pierre Bronowicki, Jean-Pierre Zarski, Odile Goria, Paul Calès, Jean-Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean-Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean-Didier Grangé, Catherine Buffet, Yannick Bacq, Claire Wartelle, Thông Dao, Yves Benhamou, Christophe Pilette, Christine Silvain, Christos Christidis, Dominique Capron, Gérard Thiefin, Sophie Hillaire, Vincent Di Martino, Pierre Nahon, Sylvie Chevret, . . (2015) Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology 62, 737-750. CrossRef

  • 195

    (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62, 932-954. CrossRef

  • 196

    Inge Mannaerts, Sofia Batista Leite, Stefaan Verhulst, Sofie Claerhout, Nathalie Eysackers, Lien F.R. Thoen, Anne Hoorens, Hendrik Reynaert, Georg Halder, Leo A. van Grunsven. . (2015) The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. Journal of Hepatology 63:3, 679-688. CrossRef

  • 197

    Xavier Forns, Stuart C. Gordon, Eli Zuckerman, Eric Lawitz, Jose L. Calleja, Harald Hofer, Christopher Gilbert, John Palcza, Anita Y.M. Howe, Mark J. DiNubile, Michael N. Robertson, Janice Wahl, Eliav Barr, Maria Buti. . (2015) Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. Journal of Hepatology 63:3, 564-572. CrossRef

  • 198

    Pankaj Puri, Anil C. Anand, Vivek A. Saraswat, Subrat K. Acharya, Radha K. Dhiman, Shiv K. Sarin, Shivaram P. Singh, Yogesh K. Chawla, Rakesh Aggarwal, Deepak Amarapurkar, Anil Arora, Vinod K. Dixit, Ajit Sood, Samir Shah, Ajay Duseja, Dharmesh Kapoor, Shalimar, Kaushal Madan, Gaurav Pande, Aabha Nagral, Premashis Kar, Abraham Koshy, Amarender S. Puri, C.E. Eapen, Sandeep Thareja. . (2015) Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. Journal of Clinical and Experimental Hepatology 5:3, 221-238. CrossRef

  • 199

    Marina Berenguer. . (2015) Management of HCV in the liver transplant setting. Clinics and Research in Hepatology and Gastroenterology 39, S115-S119. CrossRef

  • 200

    Corlan O Adebajo, Nancy Reau. . (2015) Overtreating versus undertreating: what is the optimized treatment duration in HCV?. Future Virology 10:9, 1049-1056. CrossRef

  • 201

    Mitchell L Shiffman, Amy M James, April G Long, Philip C Alexander. . (2015) Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon andor Ribavirin. The American Journal of Gastroenterology 110, 1179-1185. CrossRef

  • 202

    Joseph E. Rower, Eric G. Meissner, Leah C. Jimmerson, Anu Osinusi, Zayani Sims, Tess Petersen, Lane R. Bushman, Pamela Wolfe, John G. McHutchison, Shyamasundaran Kottilil, Jennifer J. Kiser. . (2015) Serum and cellular ribavirin pharmacokinetic and concentration–effect analysis in HCV patients receiving sofosbuvir plus ribavirin. Journal of Antimicrobial Chemotherapy 70, 2322-2329. CrossRef

  • 203

    Saeed H. Al Marzooqi, Jordan J. Feld. . (2015) Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. Liver International 35, 1923-1933. CrossRef

  • 204

    Jacob Lalezari, J. Greg Sullivan, Peter Varunok, Edward Galen, Kris V. Kowdley, Vinod Rustgi, Humberto Aguilar, Franco Felizarta, Barbara McGovern, Martin King, Akshanth R. Polepally, Daniel E. Cohen. . (2015) Ombitasvirparitaprevirr and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. Journal of Hepatology 63:2, 364-369. CrossRef

  • 205

    Cindy J Bednasz, Joshua R Sawyer, Anthony Martinez, Patrick G Rose, Samantha S Sithole, Holly R Hamilton, Farzia S Kaufman, Charles S Venuto, Qing Ma, Andrew Talal, Gene D Morse. . (2015) Recent advances in management of the HIVHCV coinfected patient. Future Virology 10:8, 981-997. CrossRef

  • 206

    Christoph Höner zu Siederdissen, Benjamin Maasoumy, Katja Deterding, Kerstin Port, Lisa Sollik, Carola Mix, Janina Kirschner, Janet Cornberg, Michael P. Manns, Heiner Wedemeyer, Markus Cornberg. . (2015) Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. Liver International 35:10.1111liv.2015.35.issue-7, 1845-1852. CrossRef

  • 207

    Erik De Clercq. . (2015) Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace. Reviews in Medical Virology 25:10.1002rmv.v25.4, 254-267. CrossRef

  • 208

    Yosuke Hirotsu, Tatsuo Kanda, Hiroshi Matsumura, Mitsuhiko Moriyama, Osamu Yokosuka, Masao Omata. . (2015) HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatology International 9, 424-430. CrossRef

  • 209

    K. Herzer, G. Gerken. . (2015) Therapie der Hepatitis C bei Patienten mit Zirrhose sowie vor und nach Lebertransplantation. Der Gastroenterologe 10, 297-304. CrossRef

  • 210

    K. Rajender Reddy, Marc Bourlière, Mark Sulkowski, Masao Omata, Stefan Zeuzem, Jordan J. Feld, Eric Lawitz, Patrick Marcellin, Tania M. Welzel, Robert Hyland, Xiao Ding, Jenny Yang, Steven Knox, Phillip Pang, Hadas Dvory-Sobol, G. Mani Subramanian, William Symonds, John G. McHutchison, Alessandra Mangia, Edward Gane, Masashi Mizokami, Stanislas Pol, Nezam Afdhal. . (2015) Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Hepatology 62, 79-86. CrossRef

  • 211

    (2015) EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatology 63:1, 199-236. CrossRef

  • 212

    Rajeev M. Menon, Prajakta S. Badri, Tianli Wang, Akshanth R. Polepally, Jiuhong Zha, Amit Khatri, Haoyu Wang, Beibei Hu, Eoin P. Coakley, Thomas J. Podsadecki, Walid M. Awni, Sandeep Dutta. . (2015) Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevirritonavir, ombitasvir, and dasabuvir. Journal of Hepatology 63:1, 20-29. CrossRef

  • 213

    Donald Jensen, Kenneth E. Sherman, Christophe Hézode, Stanislas Pol, Stefan Zeuzem, Victor de Ledinghen, Albert Tran, Magdy Elkhashab, Ziad H. Younes, Marcelo Kugelmas, Stefan Mauss, Gregory Everson, Velimir Luketic, John Vierling, Lawrence Serfaty, Maurizia Brunetto, Jeong Heo, David Bernstein, Fiona McPhee, Delphine Hennicken, Patricia Mendez, Eric Hughes, Stephanie Noviello. . (2015) Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. Journal of Hepatology 63:1, 30-37. CrossRef

  • 214

    G. J. Dore, J. J. Feld. . (2015) Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir". Clinical Infectious Diseases 60, 1829-1836. CrossRef

  • 215

    Emma D. Deeks. . (2015) OmbitasvirParitaprevirRitonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection. Drugs 75, 1027-1038. CrossRef

  • 216

    Elizabeth C. Verna, Jacqueline G. O’Leary. . (2015) Hepatitis C treatment in patients on the liver transplant waiting list. Current Opinion in Organ Transplantation 20, 242-250. CrossRef

  • 217

    Harald H. Kessler, Bryan R. Cobb, Heiner Wedemeyer, Benjamin Maasoumy, Veronique Michel-Treil, Luca Ceccherini-Nelli, Birgit Bremer, Margit Hübner, Anna Helander, Hacene Khiri, Gabrielle Heilek, Christian O. Simon, Kevin Luk, Shagufta Aslam, Philippe Halfon. . (2015) Evaluation of the COBAS® AmpliPrepCOBAS® TaqMan® HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. Journal of Clinical Virology 67, 67-72. CrossRef

  • 218

    Ani A. Kardashian, Jennifer C. Price. . (2015) Hepatitis C virus–HIV-coinfected patients and liver transplantation. Current Opinion in Organ Transplantation 20, 276-285. CrossRef

  • 219

    Kirpal Kaur, Mona A. Gandhi, Judianne Slish. . (2015) Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications. Infectious Diseases and Therapy 4, 159-172. CrossRef

  • 220

    Raoel Maan, Adriaan J van der Meer, Bettina E Hansen, Jordan J Feld, Heiner Wedemeyer, Jean-François Dufour, Frank Lammert, Michael P Manns, Stefan Zeuzem, Harry L A Janssen, Robert J de Knegt, Bart J Veldt. . (2015) Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. Journal of Gastroenterology and Hepatology 30, 1057-1064. CrossRef

  • 221

    Tatsuya Minami, Ryosuke Tateishi, Masyuko Kondo, Ryo Nakagomi, Naoto Fujiwara, Masaya Sato, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, Yoshinari Asaoka, Yuji Kondo, Kyoji Moriya, Shuichiro Shiina, Kazuhiko Koike. . (2015) Serum Alpha-Fetoprotein Has High Specificity for the Early Detection of Hepatocellular Carcinoma After Hepatitis C Virus Eradication in Patients. Medicine 94, e901. CrossRef

  • 222

    Ingmar Wolffram, David Petroff, Olaf Bätz, Katrin Jedrysiak, Jan Kramer, Hannelore Tenckhoff, Thomas Berg, Johannes Wiegand. . (2015) Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. Journal of Hepatology 62:6, 1256-1264. CrossRef

  • 223

    Christophe Hézode, Tarik Asselah, K Rajender Reddy, Tarek Hassanein, Marina Berenguer, Katarzyna Fleischer-Stepniewska, Patrick Marcellin, Coleen Hall, Gretja Schnell, Tami Pilot-Matias, Niloufar Mobashery, Rebecca Redman, Regis A Vilchez, Stanislas Pol. . (2015) Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. The Lancet 385:9986, 2502-2509. CrossRef

  • 224

    Nesrine Gamal, Giovanni Vitale, Pietro Andreone. . (2015) Paritaprevir in patients with chronic hepatitis C genotype 1. Future Virology 10:6, 679-690. CrossRef

  • 225

    Samuel W Brayer, K Rajender Reddy. . (2015) Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy. Expert Review of Gastroenterology & Hepatology 9, 547-558. CrossRef

  • 226

    Adriaan J van der Meer. . (2015) Achieving sustained virological response: what’s the impact on further hepatitis C virus-related disease?. Expert Review of Gastroenterology & Hepatology 9, 559-566. CrossRef

  • 227

    P. Badri, S. Dutta, E. Coakley, D. Cohen, B. Ding, T. Podsadecki, B. Bernstein, W. Awni, R. Menon. . (2015) Pharmacokinetics and Dose Recommendations for Cyclosporine and Tacrolimus When Coadministered With ABT-450, Ombitasvir, and Dasabuvir. American Journal of Transplantation 15, 1313-1322. CrossRef

  • 228

    S. Bruno, S. Bollani, A. L. Zignego, J. M. Pascasio, C. Magni, A. Ciancio, M. Caremani, A. Mangia, S. Marenco, S. Piovesan, L. Chemello, S. Babudieri, A. Moretti, F. Gea, C. Colletta, R. Perez-Alvarez, X. Forns, J. R. Larrubia, J. Arenas, J. Crespo, V. Calvaruso, F. Ceccherini Silberstein, P. Maisonneuve, A. Craxì, J. L. Calleja, . . (2015) Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International ItalianSpanish BoceprevirPeginterferonRibavirin Name Patients Program. Journal of Viral Hepatitis 22:10.1111jvh.2015.22.issue-5, 469-480. CrossRef

  • 229

    Kazuaki Chayama, Kazuo Notsumata, Masayuki Kurosaki, Ken Sato, Lino Rodrigues, Carolyn Setze, Prajakta Badri, Tami Pilot-Matias, Regis A. Vilchez, Hiromitsu Kumada. . (2015) Randomized trial of interferon- and ribavirin-free ombitasvirparitaprevirritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology 61, 1523-1532. CrossRef

  • 230

    Dennis J. Cada, James Leonard, Terri L. Levien, Danial E. Baker. . (2015) OmbitasvirParitaprevirRitonavir and Dasabuvir. Hospital Pharmacy 50, 396-412. CrossRef

  • 231

    Suraj A. Sharma, Jordan J. Feld. . (2015) Management of HCV in Cirrhosis—a Rapidly Evolving Landscape. Current Gastroenterology Reports 17. CrossRef

  • 232

    Tamer Elbaz, Mohamed El-Kassas, Gamal Esmat. . (2015) New era for management of chronic hepatitis C virus using direct antiviral agents: A review. Journal of Advanced Research 6, 301-310. CrossRef

  • 233

    Peter Ferenci. . (2015) Treatment of hepatitis C in difficult-to-treat patients. Nature Reviews Gastroenterology & Hepatology 12, 284-292. CrossRef

  • 234

    Kurinchi Selvan Gurusamy, Douglas Thorburn, Emmanuel Tsochatzis, Brian R Davidson, Kurinchi Selvan Gurusamy. . 2015. Pharmacological treatments for acute hepatitis C infection: a network meta-analysis. Cochrane Database of Systematic Reviews. CrossRef

  • 235

    Ashley Arezou Minaei, Kris V Kowdley. . (2015) ABT-450ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus. Expert Opinion on Pharmacotherapy 16, 929-937. CrossRef

  • 236

    Yao-Chun Hsu, Chun-Ying Wu, Jaw-Town Lin. . (2015) Hepatitis C Virus Infection, Antiviral Therapy, and Risk of Hepatocellular Carcinoma. Seminars in Oncology 42, 329-338. CrossRef

  • 237

    M.D. Schneider, B. Kronenberger, S. Zeuzem, C. Sarrazin. . (2015) Therapie der Hepatitis C. Der Internist 56, 391-405. CrossRef

  • 238

    Audrey Coilly, Bruno Roche, Jean-Charles Duclos-Vallée, Didier Samuel. . (2015) Management of post transplant hepatitis C in the direct antiviral agents era. Hepatology International 9, 192-201. CrossRef

  • 239

    Jennifer C. Price, Norah A. Terrault. . (2015) Treatment of hepatitis C in liver transplant patients: Interferon out, direct antiviral combos in. Liver Transplantation 21:10.1002lt.v21.4, 423-434. CrossRef

  • 240

    Gina Choi, Kristina G. Lee, Crystal Wu, Sammy Saab. . (2015) Kidney Transplantation Threshold in Patients With Hepatitis C. Transplantation 99, 829-834. CrossRef

  • 241

    Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, Christophe Hézode, Fabien Zoulim, Philippe Mathurin, Albert Tran, Dominique G Larrey, Vlad Ratziu, Laurent Alric, Robert H Hyland, Deyuan Jiang, Brian Doehle, Phillip S Pang, William T Symonds, G Mani Subramanian, John G McHutchison, Patrick Marcellin, François Habersetzer, Dominique Guyader, Jean-Didier Grangé, Véronique Loustaud-Ratti, Lawrence Serfaty, Sophie Metivier, Vincent Leroy, Armand Abergel, Stanislas Pol. . (2015) Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). The Lancet Infectious Diseases 15, 397-404. CrossRef

  • 242

    Ming-Lung Yu, Ming-Lun Yeh, Pei-Chien Tsai, Ching-I. Huang, Jee-Fu Huang, Chung-Feng Huang, Meng-Hsuan Hsieh, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Wen-Yi Lin, Nai-Jen Hou, Zu-Yau Lin, Shinn-Cherng Chen, Chia-Yen Dai, Wan-Long Chuang, Wen-Yu Chang. . (2015) Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C. Medicine 94, e690. CrossRef

  • 243

    Brian L. Pearlman, Carole Ehleben, Michael Perrys. . (2015) The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C– Child's Class A Cirrhosis. Gastroenterology 148:4, 762-770.e2. CrossRef

  • 244

    Christoph Welsch, Katrin Haselow, Jérôme Gouttenoire, Markus Schneider, Kenichi Morikawa, Yolanda Martinez, Simone Susser, Christoph Sarrazin, Stefan Zeuzem, Iris Antes, Darius Moradpour, Christian M. Lange. . (2015) Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage. Journal of Hepatology 62:4, 779-784. CrossRef

  • 245

    Jean-Michel Pawlotsky, Jordan J. Feld, Stefan Zeuzem, Jay H. Hoofnagle. . (2015) From non-A, non-B hepatitis to hepatitis C virus cure. Journal of Hepatology 62:1, S87-S99. CrossRef

  • 246

    Geoffrey Dusheiko, Douglas MacDonald. . (2015) Hope for non-responders with hepatitis C virus and cirrhosis. The Lancet Infectious Diseases 15:4, 363-365. CrossRef

  • 247

    R. Buchanan, T. Hydes, S. I. Khakoo. . (2015) Innate and adaptive genetic pathways in HCV infection. Tissue Antigens 85:4, 231-240. CrossRef

  • 248

    Evan B. Cunningham, Tanya L. Applegate, Andrew R. Lloyd, Gregory J. Dore, Jason Grebely. . (2015) Mixed HCV infection and reinfection in people who inject drugs—impact on therapy. Nature Reviews Gastroenterology & Hepatology 12, 218-230. CrossRef

  • 249

    Juan Pablo Trivella, Julio Gutierrez, Paul Martin. . (2015) Dasabuvir: a new direct antiviral agent for the treatment of hepatitis C. Expert Opinion on Pharmacotherapy 16, 617-624. CrossRef

  • 250

    Kosh Agarwal, Ashley Barnabas. . (2015) Faldaprevir for the treatment of genotype-1 hepatitis C virus. Expert Review of Gastroenterology & Hepatology 9, 277-288. CrossRef

  • 251

    Nesrine Gamal, Giovanni Vitale, Pietro Andreone. . (2015) ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients. Expert Review of Anti-infective Therapy 13, 295-304. CrossRef

  • 252

    J.-M. Pawlotsky. . (2015) Viral entry inhibition: too late for hepatitis C, but promising for other viral infections. Gut 64, 362-364. CrossRef

  • 253

    Daniel P Webster, Paul Klenerman, Geoffrey M Dusheiko. . (2015) Hepatitis C. The Lancet 385, 1124-1135. CrossRef

  • 254

    Maria-Carlota Londoño, Javier Hernández-Blanco, Alvaro Díaz-Gonzalez. . (2015) Sustained Virological Response and Hepatitis C- Cirrhosis: a World of Opportunities. Current Hepatology Reports 14, 32-39. CrossRef

  • 255

    Jean-Michel Pawlotsky. . (2015) Hepatitis C Treatment: The Data Flood Goes on—An Update From the Liver Meeting 2014. Gastroenterology 148, 468-479. CrossRef

  • 256

    Markus Cornberg, Michael P Manns. . (2015) New kids on the block—step by step to an ideal HCV therapy. The Lancet 385, 1050-1052. CrossRef

  • 257

    M. D. Sadler, S. S. Lee. . (2015) Revolution in hepatitis C antiviral therapy. British Medical Bulletin 113, 31-44. CrossRef

  • 258

    Graham R Foster. . (2015) Shorter treatments for hepatitis C: another step forward?. The Lancet 385, 1054-1055. CrossRef

  • 259

    Eric Lawitz, Edward Gane, Brian Pearlman, Edward Tam, Wayne Ghesquiere, Dominique Guyader, Laurent Alric, Jean-Pierre Bronowicki, Laura Lester, William Sievert, Reem Ghalib, Luis Balart, Fredrik Sund, Martin Lagging, Frank Dutko, Melissa Shaughnessy, Peggy Hwang, Anita Y M Howe, Janice Wahl, Michael Robertson, Eliav Barr, Barbara Haber. . (2015) Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. The Lancet 385, 1075-1086. CrossRef

  • 260

    C. Nelson Hayes, Kazuaki Chayama. . (2015) Emerging treatments for chronic hepatitis C. Journal of the Formosan Medical Association 114, 204-215. CrossRef

  • 261

    Hezhao Ji, Robert A. Kozak, Mia J. Biondi, Richard Pilon, Dominic Vallee, Ben Binhua Liang, David La, John Kim, Gary Van Domselaar, Lynne Leonard, Paul Sandstrom, James Brooks. . (2015) Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 477, 1-9. CrossRef

  • 262

    Juan Oliva-Moreno, Luz M. Peña-Longobardo, Sonia Alonso, Antonio Fernández-Bolaños, María Luisa Gutiérrez, Álvaro Hidalgo-Vega, Elsa de la Fuente, Conrado M. Fernández-Rodríguez. . (2015) Labour productivity losses caused by premature death associated with hepatitis C in Spain. European Journal of Gastroenterology & Hepatology, 1. CrossRef

  • 263

    Lindsey M. Childs-Kean, Elizabeth O. Hand. . (2015) Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection. Clinical Therapeutics 37, 243-267. CrossRef

  • 264

    Eric Lawitz, Greg Sullivan, Maribel Rodriguez-Torres, Michael Bennett, Fred Poordad, Mudra Kapoor, Prajakta Badri, Andrew Campbell, Lino Rodrigues, Yiran Hu, Tami Pilot-Matias, Regis A. Vilchez. . (2015) Exploratory trial of ombitasvir and ABT-450r with or without ribavirin for HCV genotype 1, 2, and 3 infection. Journal of Infection 70, 197-205. CrossRef

  • 265

    Ann-Sofi Duberg, Sarah Blach, Karolin Falconer, Martin Kåberg, Homie Razavi, Soo Aleman. . (2015) The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scandinavian Journal of Gastroenterology 50, 233-244. CrossRef

  • 266

    J. C. Hsiang, W. W. Bai, Z. Raos, W. Stableforth, A. Upton, S. Selvaratnam, E. J. Gane, S. J. Gerred. . (2015) Epidemiology, disease burden and outcomes of cirrhosis in a large secondary care hospital in South Auckland, New Zealand. Internal Medicine Journal 45:2, 160-169. CrossRef

  • 267

    Philipp Dutkowski, Michael Linecker, Michelle L. DeOliveira, Beat Müllhaupt, Pierre-Alain Clavien. . (2015) Challenges to Liver Transplantation and Strategies to Improve Outcomes. Gastroenterology 148:2, 307-323. CrossRef

  • 268

    Jordan J. Feld, Ira M. Jacobson, Donald M. Jensen, Graham R. Foster, Stanislas Pol, Edward Tam, Maciej Jablkowski, Hanna Berak, John M. Vierling, Eric M. Yoshida, Héctor R. Perez-Gomez, Astrid Scalori, Gregory J. Hooper, Jorge A. Tavel, Mercidita T. Navarro, Saba Shahdad, Rohit Kulkarni, Sophie Le Pogam, Isabel Nájera, Simon Eng, Chin Yin Lim, Nancy S. Shulman, Ellen S. Yetzer. . (2015) Randomized study of danoprevirritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferonribavirin. Journal of Hepatology 62:2, 294-302. CrossRef

  • 269

    Maria-Carlota Londoño, Christie Perelló, Joaquín Cabezas, Nuria Cañete, Sabela Lens, Zoe Mariño, Martina Gambato, Raquel Rodríguez, Susana Menéndez, José A. Carrión, Javier Crespo, José Luis Calleja, Xavier Forns. . (2015) The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. Journal of Hepatology 62:2, 311-316. CrossRef

  • 270

    Ming V. Lin, Lindsay Y. King, Raymond T. Chung. . (2015) Hepatitis C Virus–Associated Cancer. Annual Review of Pathology: Mechanisms of Disease 10:1, 345-370. CrossRef

  • 271

    Kazuaki Chayama, Fukiko Mitsui, C Nelson Hayes. . (2015) Optimizing triple therapy and IFNRBV-free regimens for hepatitis C virus infection. Expert Review of Gastroenterology & Hepatology 9, 21-30. CrossRef

  • 272

    Josep Quer, Josep Gregori, Francisco Rodríguez-Frias, Maria Buti, Antonio Madejon, Sofia Perez-del-Pulgar, Damir Garcia-Cehic, Rosario Casillas, Maria Blasi, Maria Homs, David Tabernero, Miguel Alvarez-Tejado, Jose Manuel Muñoz, Maria Cubero, Andrea Caballero, Jose Antonio delCampo, Esteban Domingo, Irene Belmonte, Leonardo Nieto, Sabela Lens, Paloma Muñoz-de-Rueda, Paloma Sanz-Cameno, Silvia Sauleda, Marta Bes, Jordi Gomez, Carlos Briones, Celia Perales, Julie Sheldon, Lluis Castells, Lluis Viladomiu, Javier Salmeron, Angela Ruiz-Extremera, Rosa Quiles-Pérez, Ricardo Moreno-Otero, Rosario López-Rodríguez, Helena Allende, Manuel Romero-Gómez, Jaume Guardia, Rafael Esteban, Javier Garcia-Samaniego, Xavier Forns, Juan Ignacio Esteban, Y.-W. Tang. . (2015) High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods. Journal of Clinical Microbiology 53, 219-226. CrossRef

  • 273

    Vincenzo Boccaccio, Savino Bruno. . (2015) Optimal management of patients with chronic hepatitis C and comorbidities. Liver International 35:10.1111liv.2014.35.issue-s1, 35-43. CrossRef

  • 274

    Tarik Asselah, Patrick Marcellin. . (2015) Viral hepatitis: towards the eradication of HCV and a cure for HBV. Liver International 35:10.1111liv.2014.35.issue-s1, 1-3. CrossRef

  • 275

    Tarik Asselah, Patrick Marcellin. . (2015) Optimal IFN-free therapy in treatment-naïve patients with HCV genotype 1 infection. Liver International 35:10.1111liv.2014.35.issue-s1, 56-64. CrossRef

  • 276

    Mitchell L Shiffman, Yves Benhamou. . (2015) Cure of HCV related liver disease. Liver International 35:10.1111liv.2014.35.issue-s1, 71-77. CrossRef

  • 277

    Mary C. Olson, Donald Gardenier, Ira M. Jacobson. . (2015) The Revolution of Hepatitis C Treatments: Review for Nurse Practitioners. The Journal for Nurse Practitioners 11, 116-123. CrossRef

  • 278

    Salvatore Petta, Antonio Craxì. . (2015) Current and future HCV therapy: do we still need other anti-HCV drugs?. Liver International 35:10.1111liv.2014.35.issue-s1, 4-10. CrossRef

  • 279

    Joy Peter, David R. Nelson. . (2015) Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients. Liver International 35:10.1111liv.2014.35.issue-s1, 65-70. CrossRef

  • 280

    Johannes Weiß, Andreas Geier. . (2015) Hepatitis C — Update 2015. MMW - Fortschritte der Medizin 157:S3, 86. CrossRef

  • 281

    I. G. Bakulin. . (2015) Topical problems of antiviral therapy for chronic hepatitis C. Terapevticheskii arkhiv 87, 113. CrossRef

  • 282

    Alessio Aghemo, Maria Francesca Donato. . (2015) Sofosbuvir Treatment in the Pre and Post Liver Transplantation Phase: The Sooner, the Better. Gastroenterology 148:1, 13-16. CrossRef

  • 283

    Rodolfo Castro, Hugo Perazzo, Beatriz Grinsztejn, Valdilea G. Veloso, Chris Hyde. . (2015) Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective. International Journal of Hepatology 2015, 1-10. CrossRef

  • 284

    Kwo , Paul Y. , Mantry , Parvez S. , Coakley , Eoin , Te , Helen S. , Vargas , Hugo E. , Brown , Robert Jr. , Gordon , Fredric , Levitsky , Josh , Terrault , Norah A. , Burton , James R. Jr. , Xie , Wangang , Setze , Carolyn , Badri , Prajakta , Pilot-Matias , Tami , Vilchez , Regis A. , Forns , Xavier , . . (2014) An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. New England Journal of Medicine 371:25, 2375-2382.Free Full Text

  • 285

    Zobair Younossi, Linda Henry. . (2014) The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Digestive and Liver Disease 46, S186-S196. CrossRef

  • 286

    E. Rodríguez de Santiago, J. Martínez González, F. Gea Rodríguez, A. Albillos Martínez. . (2014) Actualización en el tratamiento de la hepatitis C. Medicine - Programa de Formación Médica Continuada Acreditado 11, 4103-4111. CrossRef

  • 287

    Bruno Roche, Audrey Coilly, Jean-Charles Duclos-Vallée, Didier Samuel. . (2014) Optimal Management of HCV Transplant Patients. Current Hepatology Reports 13, 304-313. CrossRef

  • 288

    H. Wedemeyer. . (2014) Therapie der Hepatitis C. Der Internist 55, 1419-1426. CrossRef

  • 289

    Graham R. Foster, Sampath De Silva. . (2014) Hepatitis C genotype 1. Current Opinion in Infectious Diseases 27, 535-539. CrossRef

  • 290

    Stanislas Pol, Anais Vallet-Pichard. . (2014) Optimal Management of HIV-HCV Coinfection. Current Hepatology Reports 13, 295-303. CrossRef

  • 291

    Navita L. Mallalieu, Mohamad H. Rahimy, Constance A. Crowley, James R. Appleman, Patrick F. Smith, James L. Freddo. . (2014) Pharmacokinetics and Pharmacodynamics of Setrobuvir, an Orally Administered Hepatitis C Virus Non-Nucleoside Analogue Inhibitor. Clinical Therapeutics 36, 2047-2063.e3. CrossRef

  • 292

    Sabela Lens, Zoe Mariño, Xavier Forns. . (2014) Efficacy of new direct acting antivirals in transplant recipients and patients with advanced disease. Digestive and Liver Disease 46, S197-S205. CrossRef

  • 293

    Guido Stirnimann. . (2014) Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opinion on Pharmacotherapy 15, 2609-2622. CrossRef

  • 294

    Tarik Asselah, Savino Bruno, Antonio Craxi. . (2014) HCV cirrhosis at the edge of decompensation: Will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?. Journal of Hepatology 61:6, 1430-1433. CrossRef

  • 295

    Paul J. Pockros. . (2014) The dawn of a new era in the treatment of HCV infection: A view from the USA. Clinical Liver Disease 4, 107-108. CrossRef

  • 296

    José Velosa, Fátima Serejo, Fernando Ramalho, Rui Marinho, Beatriz Rodrigues, Cilénia Baldaia, Miguel Raimundo, Paula Ferreira. . (2014) A practical guide for antiviral therapy of chronic Hepatitis C. GE Portuguese Journal of Gastroenterology 21, 221-230. CrossRef

  • 297

    Yujin Hoshida, Bryan C. Fuchs, Nabeel Bardeesy, Thomas F. Baumert, Raymond T. Chung. . (2014) Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. Journal of Hepatology 61:1, S79-S90. CrossRef

  • 298

    Mark S. Sulkowski. . (2014) Management of acute and chronic HCV infection in persons with HIV coinfection. Journal of Hepatology 61:1, S108-S119. CrossRef

  • 299

    Martina Gambato, Sabela Lens, Miquel Navasa, Xavier Forns. . (2014) Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. Journal of Hepatology 61:1, S120-S131. CrossRef

  • 300

    Tania Mara Welzel, Georg Dultz, Stefan Zeuzem. . (2014) Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. Journal of Hepatology 61:1, S98-S107. CrossRef

  • 301

    F. Beckerich, C. Hezode, C. Robin, J.-L. Beaumont, E. Gautier, S. Maury, C. Cordonnier. . (2014) New nucleotide polymerase inhibitors to rapidly permit hematopoietic stem cell donation from a positive HCV-RNA donor. Blood 124, 2613-2614. CrossRef

  • 302

    Scott L. Friedman, Eamonn M. M. Quigley, Keith A. Sharkey, Joseph J. Y. Sung, David C. Whitcomb. . (2014) The past 10 years of gastroenterology and hepatology—reflections and predictions. Nature Reviews Gastroenterology & Hepatology 11, 692-700. CrossRef

  • 303

    S. Pol, M. Corouge. . (2014) Treatment of hepatitis C: Perspectives. Médecine et Maladies Infectieuses 44, 449-454. CrossRef

  • 304

    Andrea De Luca, Claudia Bianco, Barbara Rossetti. . (2014) Treatment of HCV infection with the novel NS34A protease inhibitors. Current Opinion in Pharmacology 18, 9-17. CrossRef

  • 305

    Sammy Saab, Christian Jackson, MD, FACG, Jose Nieto, DO, FACG, FACP, Fritz Francois, MD, MSc, FACG. . (2014) Hepatitis C in African Americans. The American Journal of Gastroenterology 109, 1576-1584. CrossRef

  • 306

    Melissa E. Laird, Amira Mohsen, Darragh Duffy, Rasha Mamdouh, Lenaig LeFouler, Armanda Casrouge, Mai El-Daly, Mona Rafik, Mohamed Abdel-Hamid, Alexandre Soulier, Jean-Michel Pawlotsky, Christophe Hézode, Isabelle Rosa, Philippe Renard, Mostafa K. Mohamed, Philippe Bonnard, Jacques Izopet, Vincent Mallet, Stanislas Pol, Matthew L. Albert, Arnaud Fontanet. . (2014) Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. Journal of Hepatology 61:4, 770-776. CrossRef

  • 307

    Juan Macías, Karin Neukam, Nicolás Merchante, Juan A Pineda. . (2014) Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients. Expert Opinion on Pharmacotherapy 15, 1837-1848. CrossRef

  • 308

    Brian L. Pearlman, Tanna H. Lim. . (2014) You’re Not the One: Treating Subjects Co-infected with Hepatitis C Genotypes 2 and 3 and Human Immunodeficiency Virus. Digestive Diseases and Sciences 59, 1681-1683. CrossRef

  • 309

    Marc G Ghany, Naveen Gara. . (2014) QUEST for a cure for hepatitis C virus: the end is in sight. The Lancet 384:9941, 381-383. CrossRef

  • 310

    Pietro Andreone, Massimo G. Colombo, Jeffrey V. Enejosa, Iftihar Koksal, Peter Ferenci, Andreas Maieron, Beat Müllhaupt, Yves Horsmans, Ola Weiland, Henk W. Reesink, Lino Rodrigues, Yiran B. Hu, Thomas Podsadecki, Barry Bernstein. . (2014) ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection. Gastroenterology 147:2, 359-365.e1. CrossRef

  • 311

    Tarik Asselah. . (2014) Daclatasvir plus sofosbuvir for HCV infection: An oral combination therapy with high antiviral efficacy. Journal of Hepatology 61:2, 435-438. CrossRef

  • 312

    Amy A. Hirsch, Renée H. Lawrence, Elizabeth Kern, Yngve Falck-Ytter, Davis T. Shumaker, Brook Watts. . (2014) Implementation and Evaluation of a Multicomponent Quality Improvement Intervention to Improve Efficiency of Hepatitis C Screening and Diagnosis. The Joint Commission Journal on Quality and Patient Safety 40:8, 351-AP1. CrossRef

  • 313

    Anna S.F. Lok. . (2014) New all-oral HCV therapies for genotype 1: A final good-bye to interferon. Clinical Liver Disease 3:10.1002cld.v3.6, 137-140. CrossRef

  • 314

    Liang , T. Jake , Ghany , Marc G. , . . (2014) Therapy of Hepatitis C — Back to the Future. New England Journal of Medicine 370:21, 2043-2047.Full Text

  • 315

    Ferenci , Peter , Bernstein , David , Lalezari , Jacob , Cohen , Daniel , Luo , Yan , Cooper , Curtis , Tam , Edward , Marinho , Rui T. , Tsai , Naoky , Nyberg , Anders , Box , Terry D. , Younes , Ziad , Enayati , Pedram , Green , Sinikka , Baruch , Yaacov , Bhandari , Bal Raj , Caruntu , Florin Alexandru , Sepe , Thomas , Chulanov , Vladimir , Janczewska , Ewa , Rizzardini , Giuliano , Gervain , Judit , Planas , Ramon , Moreno , Christophe , Hassanein , Tarek , Xie , Wangang , King , Martin , Podsadecki , Thomas , Reddy , K. Rajender , . . (2014) ABT-450r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV. New England Journal of Medicine 370:21, 1983-1992.Free Full Text

  • 316

    E. Paintsil, Y.-C. Cheng. . 2014. Antiviral Agents☆. Reference Module in Biomedical Sciences. CrossRef

  • References:

    Pass4sure Certification Exams -
    Download Hottest Pass4sure Certification Exams - CSCPK
    Complete Pass4Sure Collection of Exams - BDlisting
    Latest Exam Questions and Answers -
    Pass your exam at first attempt with Pass4Sure Questions and Answers -
    Here you will find Real Exam Questions and Answers of every exam -
    Hottest Pass4sure Exam at
    Download Hottest Pass4sure Exam at ada.esy
    Pass4sure Exam Download from
    Pass4sure Exam Download from airesturismo
    Practice questions and Cheat Sheets for Certification Exams at linuselfberg
    Study Guides, Practice questions and Cheat Sheets for Certification Exams at brondby
    Study Guides, Study Tools and Cheat Sheets for Certification Exams at
    Study Guides, Study Tools and Cheat Sheets for Certification Exams at brainsandgames
    Study notes to cover complete exam syllabus - crazycatladies
    Study notes, boot camp and real exam Q&A to cover complete exam syllabus -
    Study notes to cover complete exam syllabus - carspecwall
    Study Guides, Practice Exams, Questions and Answers - cederfeldt
    Study Guides, Practice Exams, Questions and Answers - chewtoysforpets
    Study Guides, Practice Exams, Questions and Answers - Cogo
    Study Guides, Practice Exams, Questions and Answers - cozashop
    Study Guides, Study Notes, Practice Test, Questions and Answers - cscentral
    Study Notes, Practice Test, Questions and Answers - diamondlabeling
    Syllabus, Study Notes, Practice Test, Questions and Answers - diamondfp
    Updated Syllabus, Study Notes, Practice Test, Questions and Answers -
    New Syllabus, Study Notes, Practice Test, Questions and Answers -
    Syllabus, Study Notes, Practice Test, Questions and Answers -
    Study Guides, Practice Exams, Questions and Answers - Gimlab
    Latest Study Guides, Practice Exams, Real Questions and Answers - GisPakistan
    Latest Study Guides, Practice Exams, Real Questions and Answers - Health.medicbob
    Killexams Certification Training, Q&A, Dumps -
    Killexams Syllabus, Killexams Study Notes, Killexams Practice Test, Questions and Answers -
    Pass4sure Study Notes, Pass4sure Practice Test, Killexams Questions and Answers -
    Pass4sure Brain Dump, Study Notes, Pass4sure Practice Test, Killexams Questions and Answers - levantoupoeira
    Pass4sure Braindumps, Study Notes, Pass4sure Practice Test, Killexams Questions and Answers -
    Pass4sure Braindumps, Study Notes, Pass4sure Practice Test, Killexams Questions and Answers -
    Pass4sure study guides, Braindumps, Study Notes, Pass4sure Practice Test, Killexams Questions and Answers -
    Best Certification Resources on Internet -
    Pass4sure Study Guides and Braindumps - mehmetmetegerede